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Microengineering Approaches To Study The Human Placenta
Abstract
The placenta is essential to the progression of a successful pregnancy. This specialized organ develops
along with the fetus and mediates the transfer of all substances between mother and baby, thus dictating
fetal growth and development. Despite its critical importance, there is very little known about the
development and physiology of the placenta in utero. The initial steps of placentation early in gestation
involve the migration of trophoblasts from the growing placenta into the maternal decidua where they
undergo a coordinated process of vasculature remodeling. Abnormal trophoblast invasion can lead to
adverse pregnancy outcomes or even pregnancy loss. The regulation of this invasion and remodeling is
poorly understood due to the lack of predictive research platforms. Throughout the course of pregnancy,
the kinetics of placental transport are also crucial. The placenta must effectively and efficiently allocate
resources like nutrients between the maternal and fetal circulations. However, it also is the barrier against
fetal exposure to potentially harmful xenobiotics, like drugs. There is a need for a platform that can
accurately model these transport processes to understand how the placenta controls these dynamics. We
have leveraged organ-on-a-chip technology to create biomimetic microsystems that reconstitute these
physiological processes of implantation and placental transport. We have first developed a model of the
placental barrier, or “placenta-on-a-chip” that recapitulates the multilayered structure of the maternal-fetal
interface. This platform was utilized to study i) transplacental transport of glucose and xenobiotics and ii)
the effect of hemodynamic shear stress on the placental barrier. Next, we have developed a
microphysiological model of implantation to mimic and mechanistically investigate the process of
extravillous trophoblast invasion. This platform incorporates key decidual cell types to elucidate their
regulatory roles in the process of spiral artery remodeling. The work presented in this dissertation
represents a significant contribution to the placental biology community and will improve our
fundamental understanding of the placenta.

Degree Type
Dissertation

Degree Name
Doctor of Philosophy (PhD)

Graduate Group
Bioengineering

First Advisor
Dongeun Huh

This dissertation is available at ScholarlyCommons: https://repository.upenn.edu/edissertations/3097

MICROENGINEERING APPROACHES TO STUDY THE HUMAN PLACENTA
Cassidy Blundell
A DISSERTATION
in
Bioengineering
Presented to the Faculties of the University of Pennsylvania
in
Partial Fulfillment of the Requirements for the
Degree of Doctor of Philosophy
2018

Supervisor of Dissertation
__________________
Dan Dongeun Huh
Wilf Family Term Professor of Bioengineering
Graduate Group Chairperson
__________________
Ravi Radhakrishnan
Professor of Bioengineering and Chemical and Biomolecular Engineering
Dissertation Committee
Jason Burdick, PhD – Robert D. Bent Professor of Bioengineering
Christos Coutifaris, MD PhD – Celso-Ramon Garcia Professor of Medicine
Rebecca Wells, MD – Professor of Medicine

MICROENGINEERING APPROACHES TO STUDY THE HUMAN PLACENTA
COPYRIGHT
2018
Cassidy Blundell

This work is licensed under the
Creative Commons AttributionNonCommercial-ShareAlike 3.0
License

To view a copy of this license, visit
https://creativecommons.org/licenses/by-nc-sa/3.0/us

ACKNOWLEDGMENTS
First, I would like to thank my thesis advisor, Dr. Dan Huh, for his mentorship over
the past four years. His creativity and passion have been inspiring during my PhD
and I’ve been very fortunate to work with him as he has established and expanded
his lab at Penn. I would also like to thank all the members of the Biolines Laboratory
– past and present. From scientific discussions and technical help to lab outings,
it’s been wonderful to work with them all.

I would like to thank my thesis committee members, Dr. Jason Burdick, Dr. Christos
Coutifaris, and Dr. Rebecca Wells, for their insight and guidance. I would also like
to thank all of the members of the March of Dimes University of Pennsylvania
Prematurity Research Center, in particular: Dr. Debbie Driscoll, Dr. Sam Parry, Dr.
Becky Simmons, Dr. Rita Leite, and Megan Helfrick. The ability to collaborate with
this innovative and energetic multidisciplinary team truly transformed my PhD
experience and dissertation work. Thank you to the HHMI-NIBIB Interfaces
program leadership as well, with a special thanks to Dr. Jim Gee, Dr. Andrew
Maidment, and Dr. Ann Tiao.

Finally, I want to thank my family for their unending love and support. This work
would not have been possible without them and I am immeasurably grateful for
them.

iii

ABSTRACT

MICROENGINEERING APPROACHES TO STUDY THE HUMAN PLACENTA
Cassidy Blundell
Dan Dongeun Huh

The placenta is essential to the progression of a successful pregnancy. This
specialized organ develops along with the fetus and mediates the transfer of all
substances between mother and baby, thus dictating fetal growth and
development. Despite its critical importance, there is very little known about the
development and physiology of the placenta in utero. The initial steps of
placentation early in gestation involve the migration of trophoblasts from the
growing placenta into the maternal decidua where they undergo a coordinated
process of vasculature remodeling. Abnormal trophoblast invasion can lead to
adverse pregnancy outcomes or even pregnancy loss. The regulation of this
invasion and remodeling is poorly understood due to the lack of predictive research
platforms. Throughout the course of pregnancy, the kinetics of placental transport
are also crucial. The placenta must effectively and efficiently allocate resources
like nutrients between the maternal and fetal circulations. However, it also is the
barrier against fetal exposure to potentially harmful xenobiotics, like drugs. There
is a need for a platform that can accurately model these transport processes to
understand how the placenta controls these dynamics. We have leveraged organon-a-chip technology to create biomimetic microsystems that reconstitute these
iv

physiological processes of implantation and placental transport. We have first
developed a model of the placental barrier, or “placenta-on-a-chip” that
recapitulates the multilayered structure of the maternal-fetal interface. This
platform was utilized to study i) transplacental transport of glucose and xenobiotics
and ii) the effect of hemodynamic shear stress on the placental barrier. Next, we
have developed a microphysiological model of implantation to mimic and
mechanistically investigate the process of extravillous trophoblast invasion. This
platform incorporates key decidual cell types to elucidate their regulatory roles in
the process of spiral artery remodeling. The work presented in this dissertation
represents a significant contribution to the placental biology community and will
improve our fundamental understanding of the placenta.
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LIST OF ILLUSTRATIONS

Figure 1.1. Publications in PubMed database grouped by organ system. A. The
number of publications relating to the PubMed search query ‘placenta’ is markedly
lower than other human organ systems. The publications relating to placental biology
totals approximately 88,000 compared to over 1.7 million relating to the brain. B. The
rate of increase of the number of publications over time relating to ‘placenta’ also
significantly lags behind that of other organs, such as the brain and lungs.
Figure 1.2. Developmental origins of health and disease. Birth weight correlates to the
risk of developing cardiovascular and metabolic disease in adult life. Individuals born
SGA or LGA undergo fetal programming that predisposes them to these conditions
in adult life. Figure from Calkins et al. 2011.
Figure 1.3. Human implantation. Cytrophoblasts (CTBs) differentiate into extravillous
trophoblasts (EVTs) and invade into the maternal decidua to remodel the uterine
spiral arteries. This process is regulated by interactions between EVTs and
endothelial cells (ECs) of the uterine vasculature and neighboring stromal cells
(SCs).
Figure 1.4. Classification of villi. Three main types of chorionic villi exist in the human
placenta: intermediate, terminal, and anchoring. Intermediate villi are continuations
of the stem villi that make up the central structure of a villous tree. Terminal villi
branch off of intermediate villi and represent the maximal surface area for maternalfetal transport. The terminal villi become increasing prevalent late in gestation to
boost the degree transfer to the fetus. Anchoring villi attach the placenta to the
uterine wall.
Figure 1.5. Cross-section of chorionic villi throughout gestation. Chorionic villi in the
first trimester contain thicker stromal tissue, few fetal vessels, and are surrounded
by a layer of cytotrophoblasts and syncytium. Later in gestation, the placental barrier
of term villi has thinned to contain fewer cytotrophoblasts and less connective tissue.
The fetal vasculature has grown significantly and the syncytiotrophoblast and fetal
x

endothelial cells are in close apposition, separated in some areas by only a thin
basement membrane for maximal efficiency of maternal-fetal transport.
Figure 1.6. Mechanisms of cellular transport. Specialized protein transporters mediate
transfer of substances across the cell membrane. In passive diffusion, molecules
freely pass through the cell membrane without energy input based on characteristics
like size, charge, and lipophilicity. In facilitated diffusion, transfer down a
concentration gradient across the membrane is mediated by transmembrane protein
transporters. No energy is required for this process. Finally, active transport is
transporter-mediated passage of molecules against a concentration gradient that
requires ATP or another source of energy. Placental transport falls into these three
main categories.
Figure 1.7. Spiral artery remodeling. Spiral arteries are uterine vessels located in the
endometrium. During implantation in a normal pregnancy, cytotrophoblasts invade
into the decidua and remodel the spiral arteries to convert them to low resistance
vessels. In an abnormal pregnancy, this process does not proceed correctly and
there is insufficient remodeling of the uterine vasculature. This leads to inadequate
placental perfusion during gestation.
Figure 1.8. Microengineered platforms to study the human placenta. A. Photograph
of the placenta-on-a-chip microdevice. The two microchannels, colored in red and
blue respectively, enable compartmentalized co-culture of the two key cell types of
the human placental barrier. B. Photograph of the implantation-on-a-chip
microdevice. The three compartment system enables reconstitution of the uterine
stroma to model and investigate the process of human implantation.
Figure 2.1. The human placental barrier. A. Schematic of a human fetus and placenta
within the uterine cavity. The placenta is anchored to the uterine wall and connected
to the developing fetus via the umbilical cord.

B. Cross-sectional view of the

placenta illustrates the placental cotyledons. Each cotyledon consists of a stem
chorionic villus and its branches. These villi are in direct contact with maternal blood
in the intervillous space. C. The maternal intervillous space is separated from the
lumen of the fetal capillary by the maternal-fetal interface composed of the
xi

syncytiotrophoblast, basal lamina, and villous endothelial cells.

D. The three-

dimensional microarchitecture of the placental barrier is reconstituted within our
microengineered system.

The placenta-on-a-chip consists of upper and lower

microchannels separated by a thin, semipermeable membrane. Trophoblast cells
are cultured in the upper microchannel on the apical side of the membrane, and
villous endothelial cells are grown in the lower microchannel on the basal side of the
membrane.
Figure 2.2. Fabrication of the placenta-on-a-chip microdevice. A. Schematic of device
bonding. Two PDMS layers containing a hollow microchannel are bonded with a
semipermeable membrane (shown in tan) sandwiched between. B. A scanning
electron microscope image of the cross-section of the fully bonded device illustrates
the dual channel system of the placenta-on-a-chip. The upper microchannel
represents the maternal circulation and the lower microchannel represents the fetal
circulation. A higher magnification image depicts the porosity of the intervening
polymeric membrane.
Figure 2.3. Microengineered placental barrier. A. Three-dimensional rendering of the
microengineered placental barrier. The trophoblast and endothelial cell populations
are stained for E-cadherin (red) and VE-cadherin (green), respectively. Nuclei are
shown in blue.

Scale bar: 30 μm.

microengineered barrier.

B. Cross-sectional view of the same

Scale bar: 30 μm.

C. The trophoblast cells form a

continuous network of epithelial adherens junctions (E-cadherin, red). Nuclei are
stained with DAPI (blue). Scale bar: 20 μm. D. The placental villous endothelium
also displays intact cell-cell junctions (VE-cadherin, red). Green and blue show actin
and nuclear staining, respectively. Scale bar: 20 μm. E. The trophoblast cells
produce laminin (green) during culture in our microdevice. The image shows cells
on Day 6. Scale bar: 30 μm. F. Cross-sectional view of laminin deposition. Laminin
is stained green, and trophoblast nuclei are labeled in blue. The location of the cell
culture membrane is indicated by the dotted line. Scale bar: 10 μm.
Figure 2.4. Microvilli formation on-chip. A. Trophoblast cells cultured under dynamic
flow conditions in the placenta-on-a-chip show widespread microvilli formation on
the apical cell surface. Scale bar: 15 μm. B. Three-dimensional rendering of
xii

microvilli on the surface of BeWo cells in the placenta-on-a-chip. Scale bar: 20 μm.
C. Microvilli in BeWo cells cultured in Transwell appear finer and significantly less
abundant. Scale bar: 15 μm. D. Quantification of relative fluorescence of microvilli
F-actin (green) in static and dynamic culture conditions.
counterstained with DAPI (blue).

Cell nuclei were

The intensity of fluorescence generated by

microvilli was increased substantially when the trophoblast cells were grown under
flow conditions in the placenta-on-a-chip, as compared to static Transwell culture
Figure 2.5. Trophoblast syncytialization. A. In the human placenta, cytotrophoblast
cells in early gestation go through a process of cell fusion to form a multinucleated
syncytiotrophoblast.

The resulting syncytium makes up the outer lining of the

chorionic villi that comes into contact with maternal blood in the intervillous space.
B. The BeWo cells cultured in our model exhibit high levels of E-cadherin (red)
expression prior to forskolin treatment (left). Continuous epithelial exposure to
forskolin over 72 hours induces trophoblasts to undergo cell-cell fusion, leading to
nuclear aggregation and deceased expression of epithelial junctions. C. During
forskolin-induced syncytialization, the permeability of the microengineered barrier to
dextran decreases over time.

* represents a statistically significant difference

between 24 h and 72h, as well as between 48h and 72h. D. The BeWo cells produce
increasing levels of β-human chorionic gonadotropin (β-HCG) over 120 hours of
forskolin treatment (red bars). Hormone secretion by untreated cells is negligible.
Figure 2.6. Transplacental glucose transport. A. The syncytial epithelium in our model
expresses high levels of GLUT1 transporters (red). Blue shows DAPI staining.
Scale bar: 10 μm. B. This cross-sectional view of the trophoblasts shows the
asymmetric localization of GLUT1 transporters to the apical membrane. Scale bar:
5 μm. C. Immunofluorescence staining of GLUT1 on the apical side is substantially
stronger than that on the basal side. D. A concentration gradient of glucose (green
dots) is generated across the microengineered placental barrier to drive glucose
transport from the maternal to fetal compartments. E. Percent increase in fetal
glucose concentration for the bare membrane, trophoblast monoculture, and coculture conditions. F. The percent rate of glucose transfer in the placenta-on-a-chip
device is similar to that measured in the perfused ex vivo placenta.
xiii

Figure 3.1. The placental intervillous space is a dynamic fluid environment. Red
arrows denoting hemodynamics in the maternal intervillous compartment illustrate
the

complex

mechanical

microenvironment

within

the

placenta.

The

syncytiotrophoblast of the chorionic villi, which is bathed in maternal blood, is in
direct contact with these mechanical forces. Until recently, very little was known
about the fluid dynamics of the placental intervillous space. However, recent work
has determined levels of fluid shear stress experienced at the surface of the
chorionic villi.
Figure 3.2. Changes in E-cadherin expression in response to fluid shear stress. A.
Following 72 hours of static culture, BeWo cells exhibited continuous E-cadherin
(red) expression throughout the cell monolayer. No significant aggregation of fusion
has occurred. Nuclei are counterstained with DAPI (blue). Scale bar = 30 µm. B. At
24 hours of microfluidic culture, BeWo exhibited a cytotrophoblast-like morphology
with widespread E-cadherin staining. Scale bar = 30 µm. C. Exposure to low shear
stress (left) and high shear stress (right) for 72 hours led to reduction in E-cadherin
expression in some areas of the BeWo monolayer. Scale bar = 30 µm.
Figure 3.3. b-hCG production in response to fluid shear stress. A. Static culture yields
no detectable synthesis of b-hCG (green). E-cadherin is stained in red and nuclei
are labeled with DAPI in blue. Scale bar = 30 µm. B. Low shear stress on-chip leads
to low levels of b-hCG in some cells. Scale bar = 30 µm. C. Exposure to high shear
stress has increasing levels of b-hCG compared to the low shear condition. Areas of
protein biosynthesis coincide with dissolution of E-cadherin junctions. Scale bar =
30 µm. D. As a positive control, forskolin treatment in static culture induces b-hCG
production in a small number of cells throughout the BeWo monolayer. Scale bar =
30 µm. E. Quantitative real-time PCR shows a shear stress level-dependent
increase in b-hCG mRNA expression. All expression was normalized to GAPDH and
fold change was calculated from static culture control.
Figure 3.4. Forskolin-induced fusion was increased by exposure to shear stress. A.
In static culture, forskolin treatment leads to morphological changes and biochemical
differentiation with b-hCG production (green). However, many cells in the BeWo
population retain a cytotrophoblast-like morphology, as illustrated by E-cadherin
xiv

expression (red). Nuclei are counterstained with DAPI (blue). Scale bar = 30 µm. B.
A combination of shear stress and forskolin treatments yields b-hCG synthesis and
a more pronounced loss in E-cadherin expression in BeWo cells. Scale bar = 30 µm.
C. At day 3, qPCR analysis shows a large increase in b-hCG mRNA expression with
forskolin treatment. This expression is further increased with combined forskolin and
shear stress exposure. All mRNA expression was normalized to GAPDH and fold
expression was calculated from a static control.
Figure 4.1. The human placenta and placenta-on-a-chip. A. Three-dimensional cross
section of the human placenta illustrates cotyledons, which contain chorionic villi
bathed in the maternal blood in the intervillous space. B. A zoomed-in view highlights
the fetal capillaries that are located within the chorionic villi. C. The placental barrier
that separates the maternal intervillous space from the fetal capillary lumen consists
of two cell types: the syncytiotrophoblast and fetal endothelial cells separated by a
thin interstitial tissue layer. D-E. The placenta-on-a-chip is a microengineered model
designed to recapitulate the multi-layered three-dimensional architecture of the
placental barrier. Within the device, trophoblast and endothelial cells are co-cultured
on the opposite sides of a thin porous polymeric membrane. During culture, the
viability of the cells is maintained by continuous low of culture medium on both sides
of the membrane.
Figure 4.2. Microengineered in vitro placental barrier. A. BeWo cells cultured on the
upper side of the porous membrane form a continuous epithelial barrier. Red shows
E-cadherin staining. Scale bar: 55 μm. B. Human placental villous endothelial cells
(HPVECs) are grown to confluence on the lower side of the membrane. Widespread
expression of VE-cadherin (green) illustrates the structural integrity of the endothelial
tissue. Scale bar: 36 μm. C. The microengineered placental barrier effectively
prevents the transfer of FITC-inulin from the maternal microchannel to the fetal
compartment, demonstrating appropriate barrier function. D. Dense microvilli cover
the surface of the BeWo cell population, as illustrated by F-actin staining (green).
Scale bar: 20 μm. E. A cross-sectional view of actin-stained BeWo cells reveals the
apical microvilli projections protruding from the cell body. Scale bar: 6 μm.
Figure 4.3. Microengineered in vitro placental barrier. A. Extended forskolin treatment
induces a significant loss of intercellular junctions (red) and syncytialization-like cell
xv

fusion in BeWo cells over the course of 72 hours. Scale bars: 55 μm. Blue shows
nuclear staining. B. During image analysis of E-cadherin staining, individual cells are
pseudo-colored to delineate cell-cell junctions and to quantify cell area during
forskolin treatment. The average area of BeWo cells increases over 72 hours,
illustrating progressive cell fusion in the trophoblast population. C. Another method
for image analysis of cell fusion is to segment DAPI-stained nuclei of BeWo cells
and then measure the area of the segmented nuclei. The average size of cell nuclei
increases during forskolin treatment.
Figure 4.4. Drug transport in the placenta-on-a-chip. A. The kinetics of drug transport
across the microengineered placental barrier is examined by perfusing the maternal
microchannel with fluorescently labeled substrate and measuring fluorescence in the
perfusates. B. Transfer of fluorescein-heparin from the maternal compartment to the
fetal chamber is evaluated by measuring mean fluorescence intensity (MFI) of
perfusate collected from the fetal microchannel. Acellular devices allow a significant
fraction of maternally administered heparin to move across the membrane into the
fetal compartment, whereas the barrier covered with trophoblast cells and
endothelial cells (co-culture) effectively blocks heparin transport. C. BeWo cells
exhibit widespread expression of BCRP (red). Blue shows cell nuclei. Scale bar: 36
μm. D. BCRP is localized to the maternal-facing microvillous membrane of BeWo
cells. Scale bar: 36 μm.
Figure 4.5. Drug transport in the placenta-on-a-chip. A. In the co-culture model, a
continuous increase in the fluorescence of maternal perfusate indicates transportermediated efflux of glyburide back into the maternal circulation. The fluorescence of
perfusate from the fetal compartment remains low and constant, showing limited
transfer. B. Under endothelial cell monoculture conditions, maternal glyburide
concentration is decreased. C. Microscopic analysis illustrates accumulation of
glyburide in the BeWo cell monolayer, but no visible fluorescence in the HPVEC
population.
Figure 4.6. Inhibition of BCRP. A. Addition of Ko143, a BCRP inhibitor, results in
decreased maternal glyburide levels as compared to the control perfusion. This is
attributable to inhibition of efflux function of BCRP. B. The levels of fetal glyburide in
xvi

the inhibitor condition are not significantly different from those in the control group
without the inhibitor. Passage of glyburide to the fetal compartment remains very low
over the course of drug perfusion in both groups. C. Increased drug accumulation in
BeWo cells due to reduced activity of BCRP is evident from fluorescence imaging of
the cells. D. In the presence of the inhibitor, the cells show significantly higher levels
of fluorescence, suggesting increased intracellular drug retention.
Figure 5.1. Soluble factors impacting extravillous trophoblast invasion. Decidual
cells secrete soluble factors that regulate EVT invasion by promoting or inhibiting
migratory function. Adapted from [Knofler 2012].
Figure 5.2. Image analysis of invasion area. A. A 5X tile scan image is acquire every
24 hours during the experimental culture period. During analysis, the area of the gel
that intervenes between the EVT and EC channels is selected and cropped. B. The
CellTracker channel is converted to grayscale and thresholded to segment for EVTs.
C. A binary image is generated and a pixel count enables quantification of percent
area of invasion.
Figure 5.3. Implantation-on-a-chip system. A. Schematic of in vivo EVT migration in the
maternal decidua. B. Photograph of the IOC microdevice. C. The IOC chip consists
of three main compartments: an EVT channel, ECM hydrogel, and EC channel. D.
EVTs invade into the central ECM gel and migrate towards the EC compartment.
Figure 5.4. Primary EVT invasion is enhanced by the presence of HEMECs. EVTs
invade from the upper microchannel through the ECM gel in monoculture (top row)
and co-culture (bottom row) conditions. Migration of EVTs occurs in both conditions,
highlighting the inherent invasiveness of the cells. The degree of invasion is
increased in co-culture with HEMECs.
Figure 5.5. Microphysiological implantation model. A. Top-down view of the
implantation-on-a-chip at 72 hours of culture. EVTs have reached the endothelial
cell compartment. Cells are stained for F-actin (green) and nuclei (blue; DAPI).
Laminin present in the ECM is stained red. B. An isometric view of the microdevice
illustrates the 3D invasion of EVTs and endothelial tube in the EC channel. C. A
xvii

zoomed view of the hydrogel-EC interface depicts the areas at which EVTs come
into direct contact with HEMECs.
Figure 5.6. Effects of TGF-b treatment. A. TGF-b reduces EVT migration compared to
untreated devices in both monoculture and co-culture groups. Microdevices were
imaged at 72 hours of culture. EVTs are stained with CellTracker Green and nuclei
are labeled in blue with DAPI. B. The percent area of invasion in the gel lane was
quantified using FIJI image analysis.
Figure 5.7. Human uterine fibroblast culture on-chip. At left, a phase microscopy
image depicts the co-culture of EVTs, HUFs, and ECs. The upper right image shows
CellTracker Green-stained EVTs and the lower right shows CellTracker Red-stains
HUFs from the zoomed field of view outlined in red.
Figure 6.1. On-chip primary villous trophoblast culture. A. Primary human villous
trophoblasts (HVTs) stained with Cell Tracker Green cultured in the placenta-on-achip form a nearly confluent monolayer. Scale bar = 250 µm. B. HVTs exhibit areas
of nuclear aggregation. Nuclei stained with DAPI in blue. Scale bar = 50 µm. C.
Microvilli formation has occurred on the apical surface of HVTs, as shown with Factin in green. Scale bar = 20 µm.
Figure 6.2. Stem cell-derived trophoblasts. A. H9 embryonic stem cells treated with
BMP4 (100 ng/mL) exhibit morphological changes during differentiation compared
to an FGF2 (4 ng/mL) control. B. Syncytialization is present in a population of iPSC
derived trophoblasts at day 7.
Figure 6.3. Techniques for fabrication of decellularized ECM membranes. A. A side
view highlights the thinness of a decellularized ECM membrane. Tweezers are used
to pull a dECM membrane off the surface of a slab of PDMS. B. Our lab’s proprietary
dECM membrane fabrication techniques enable generation of an extremely
transparent membrane, as highlighted here (membrane placed over the word
“decellularization” in the center of the image). This is an essential property for cell
culture applications, as membrane transparency enables visualization of cells
cultured on the dECM substrate using conventional epifluorescence and confocal
microscopy.
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CHAPTER 1. Introduction and Overview

1.1 The Placenta and its Role in Lifelong Health

The placenta is a unique and transient organ that is fundamental to fetal growth and
development. During pregnancy, it regulates the transport of all substances, ranging from
nutrients and gases to waste and xenobiotics, between the mother and fetus1. This
process of maternal-fetal transfer is essential to both provide the materials that the
developing fetus requires for growth, as well as to protect it against foreign insults2.
Furthermore, recent research has established a link between fetal life and risk of chronic
disease in adult life3. Thus, fetal programming has a lifelong impact on a person’s risk of
developing metabolic diseases, such as cardiovascular disease and diabetes, which
present significant morbidity and mortality4. For example, individuals born at a low birth
weight are more likely to die from coronary artery disease. This relationship is also
associated with placental efficiency, as the placenta-to-fetus weight ratio correlates with
increased risk of adult disease5. Consequently, the placenta plays an important part in an
individual’s life from pregnancy and onwards. However, despite the critical importance of
the placenta in both fetal and maternal health, it has been referred to as one of the least
understood organs in the human body. There has been a lack of research efforts and
funding in the field of placental research, as compared to other organ systems (Figure
1.1A). In response to this, the National Institutes of Health recently launched the Human
Placenta Project to fund interdisciplinary research and encourage development of novel
technologies to better understand placental structure and function.
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Figure 1.1. Publications in PubMed database grouped by organ system. A. The
number of publications relating to the PubMed search query ‘placenta’ is markedly
lower than other human organ systems. The publications relating to placental biology
totals approximately 88,000 compared to over 1.7 million relating to the brain. B. The
rate of increase of the number of publications over time relating to ‘placenta’ also
significantly lags behind that of other organs, such as the brain and lungs.
Throughout the course of pregnancy, the placenta is the interface between the maternal
and fetal circulations. Nutrients from the maternal diet are transported to the fetus and
metabolic waste is cleared from the fetal circulation back to the maternal blood. Aberrant
nutrient transport in conditions like gestational diabetes and fetal growth retardation can
negatively affect the fetus both in utero and postnatally6. It has been established that
hemodynamic conditions and specialized transport proteins play a role in placental
transport. However, a deep understanding of what determines maternal-fetal resource
allocation is still lacking. Much is unknown regarding the placental transfer of drugs as
well. A vast majority of expecting mothers will take at least one medication during
pregnancy, but little data exists around the extent and safety of fetal drug exposure7. This
dearth of knowledge is in part due to the limitations of current research tools to study
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placental transfer in humans. For example, animal models are limited by structural
differences and variation in transporter protein expression in the placenta and
conventional in vitro approaches do not mimic the microarchitecture or dynamic
environment of the placental barrier8. Thus, there is a need for a physiologically relevant
model of this human maternal-fetal interface to mechanistically investigate placental
transport phenomena.

1.1.1 Developmental Origins of Health and Disease
The developmental origins of health and disease hypothesis was first developed by David
Barker and his colleagues9. Their retrospective study established a correlation between
birth weight and lifelong risk of coronary heart disease. Individuals who were very low or
very high weight at birth exhibited increased risk of metabolic and cardiovascular disease
in adult life, as illustrated in Figure 1.2. This connection suggested that the in utero
environment during fetal development led to changes in metabolic programming that
persist throughout adult life. Low maternal nutrient availability and undernutrition in fetal
life predispose an individual to increased fat deposition over the course of their life, leading
to heightened risk of diseases like obesity, hypertension, and coronary artery disease. The
mechanisms governing fetal programming are likely related to epigenetic changes and
alterations in tissue differentiation in utero10. Given the fact that the placenta mediates
transport and metabolism of nutrients during gestation, it plays a fundamental role in
adapting to the in utero nutritional environment and thus this process of fetal programming.
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In order to better understand the role of the placenta in fetal programming, researchers
have examined the relation of placental weight and placental weight/birth weight ratio to
disease risk11. There also exists a U-shaped relationship between the placental weight
ratio and coronary heart disease risk, where extremes on each end of the spectrum were
associated with increased risk of death from coronary heart disease12. Thus, placental
efficiency is also correlated to lifelong likelihood of these diseases. The placenta is a
dynamic organ that can adapt both its structure and function in response to changes in
the in utero milieu.

Figure 1.2. Developmental origins of health and disease. Birth weight correlates
to risk of developing cardiovascular and metabolic disease in adult life. Individuals
born SGA or LGA undergo fetal programming that predisposes them to these
conditions in adult life. Figure from Calkins et al. 2011.
Despite the established importance of placental function and fetal development in both
perinatal and lifelong health, there is still a dearth of knowledge regarding placental
physiology and pathophysiology. Historically, the concentration and funding for research
on the placenta has lagged behind that of other human organ systems. This need for
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progress and innovation in the field of placental biology has motivated the work described
in this dissertation to develop tools to mechanistically investigate placental function and
broaden the body of knowledge around this vital organ.

1.2 Human Placental Development
1.2.1 Implantation
The placenta is a transient fetal organ that develops alongside the fetus throughout the
course of gestation. Formation of the placenta begins at the point of implantation and
continues through the third trimester. During implantation, the blastocyst attaches to the
uterine decidua and through a complex, coordinated process, both fetal and placental
development begin. Cytotrophoblasts (CTBs), which are derived from the trophectoderm
of the blastocyst, proliferate and differentiate into extravillous trophoblasts (EVTs), which
invade into the endometrium to commence the process of remodeling the maternal uterine
vasculature (Figure 1.3). The process of spiral artery remodeling converts high resistance,
low flow uterine arteries to low resistance, high flow conduits, which represents a critical
step in pregnancy that allows for increased uterine blood flow to sustain the developing
fetus.
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Dysregulation of EVT invasion can result in pathological pregnancy outcomes13,14.
Excessive invasion can lead to development of placenta accreta, a condition where
trophoblast cells migrate to the myometrial layer of the uterine wall, which is associated
with increased risk of maternal hemorrhage at the time of delivery. Conversely, shallow
invasion and insufficient remodeling of the maternal uterine vasculature can manifest in
preeclampsia, which carries risks for both the mother and baby throughout pregnancy.
Translation of work from animal models is difficult in this area, as there are major
physiological differences in implantation in other species15,16. In vitro platforms based on
traditional cell culture techniques lack the ability to model the complexity of this threedimensional, heterogeneous environment. The shortcomings of these in vivo and in vitro
models is discussed further in Chapter 1.5. Thus, researchers have not been able to fully
understand the mechanisms that regulate normal EVT invasion. It is established that
trophoblast invasion is influenced by a combination of paracrine signaling from the cells

Figure 1.3. Human implantation. Cytrophoblasts (CTBs) differentiate into
extravillous trophoblasts (EVTs) and invade into the maternal decidua to remodel the
uterine spiral arteries. This process is regulated by interactions between EVTs and
endothelial cells (ECs) of the uterine vasculature and neighboring stromal cells (SCs).
Figure
6

of the surrounding maternal decidua and autocrine factors released by EVTs. As EVTs
migrate towards the uterine vessels, endothelial cells of the spiral arteries produce signals
that regulate this invasive behavior. However, a plethora of other cells, such as uterine
natural killer (NK) cells, vascular smooth muscle cells, and decidual cells, also contribute
to the regulation of EVT migration17. Therefore, there is a need for sophisticated in vitro
platforms to probe the multicellular uterine environment during implantation and better
understand regulation of EVT activity. The improved understanding of this physiological
process that is enabled by more sophisticated in vitro models may also enable
development of effective treatments for implantation-related conditions like preeclampsia
and placenta accreta.

1.2.2 Villous development
Within the placenta, the chorionic villi are tree-like projections that float in the maternal
blood of the intervillous space (Figure 1.4). These anatomical features of the placenta
grow throughout the course of gestation and are essential to fetal development. The
chorionic villi of the term placenta can be categorized into three main types: intermediate,
terminal, and anchoring (Figure 1.4). The intermediate villi form the main stem of the
villous tree and develop early in gestation. Terminal villi, which are most abundant in the
third trimester, bud from the intermediate villi and float within the intervillous space bathed
entirely in maternal blood. These have maximal contact with the maternal circulation and
thus mediate efficient transport late in pregnancy to keep up with increasing fetal metabolic
demands. Finally, anchoring villi, as the name suggests, are attached to the decidua and
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thereby anchor the placenta to the uterine wall. The fetal vasculature located within the
chorionic villi continues to grow throughout gestation and this fetal vascular network
reaches over 500 km in length at term21.

Figure 1.4. Classification of placental villi. Three main types of chorionic villi exist
in the human placenta: intermediate, terminal, and anchoring. Intermediate villi are
continuations of the stem villi that make up the central structure of a villous tree.
Terminal villi branch off of intermediate villi and represent the maximal surface area
for maternal-fetal transport. The terminal villi become increasing prevalent late in
gestation to boost the degree transfer to the fetus. Anchoring villi attach the placenta
to the uterine wall.
The

outermost

epithelial

layer

of

the

chorionic

villi

is

the

multinucleated

syncytiotrophoblast. Beneath the syncytium, there is a layer of cytotrophoblasts and an
underlying villous core, which consists of stromal tissue containing immune cells,
fibroblasts, and the fetal vasculature. The structure villous core changes significantly
during pregnancy, as illustrated by Figure 1.5. Early in gestation, the first trimester villi
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contain few fetal vessels and a significant amount of extracellular matrix (ECM) tissue and
undifferentiated stromal cells18. As pregnancy progresses, the collagen content of the
villous core decreases while there is a significant vasculogenesis, resulting in an increase
in the number of fetal vessels19. The placental barrier thins, thus decreasing the distance
between the maternal intervillous space and fetal vessels and enabling maximally efficient
maternal-fetal transfer to keep up with increasing fetal metabolic demand. At term, the
thickness of the placental barrier is less than 5 µm, with the syncytiotrophoblast separated
from fetal endothelium by only a thin basement membrane layer20. These areas where
non-nucleated syncytium is in direct apposition to fetal endothelial cells in the third
trimester placenta are referred to as vasculosyncytial membranes, illustrated on the right
in Figure 1.518.

Figure 1.5. Cross-section of chorionic villi throughout gestation. Chorionic villi in
the first trimester contain thicker stromal tissue, few fetal vessels, and are surrounded
by a layer of cytotrophoblasts and syncytium. Later in gestation, the placental barrier
of term villi has thinned to contain fewer cytotrophoblasts and less connective tissue.
The fetal vasculature has grown significantly and the syncytiotrophoblast and fetal
endothelial cells are in close apposition, separated in some areas by only a thin
basement membrane for maximal efficiency of maternal-fetal transport.
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1.3 Maternal-fetal transport and its role in fetal development
The placenta regulates the transfer of all substances between mother and baby during
gestation. Maternal-fetal exchange begins approximately 10 weeks into gestation, though
the exact gestational time point when the placental circulation is established in the
intervillous space remains controversial22. Throughout gestation, the transport capacity of
the placenta increases to keep up with fetal metabolic needs. Nutrients are transferred
from the maternal circulation to the fetus, and metabolic waste is shuttled from the fetal
circulation to the mother for excretion since developing kidneys, liver, and other fetal
organs cannot yet process waste products. Regulation of placental transport is complex
and dynamic throughout the course of pregnancy and aberrant transport processes have
been linked to adverse pregnancy outcomes.

1.3.1. Placental nutrient transfer
Fetal development is dependent upon transport of nutrients from the maternal circulation
and fetal growth rates are directly impacted by nutrient availability during gestation. In turn,
as previously discussed, the intrauterine environment and fetal growth relate to risk of
cardiovascular and metabolic disorders in adult life. Thus, placental nutrient transport
plays an important role in fetal programming of adult disease. The processes of nutrient
transfer are primarily governed by the presence of specialized transport proteins present
on the syncytiotrophoblast and fetal endothelium. Expression of these membrane
transporters is dependent upon maternal nutrition status and in pregnancies with altered
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fetal growth, like intrauterine growth restriction or macrosomia, placental nutrient
transporter profiles are altered compared to those of placentas from healthy pregnancies2.

The mechanisms of cellular transport are illustrated in Figure 1.6. Some substances can
pass through the placental barrier by means of passive diffusion and this passage is
determined in part by a substrate’s molecular weight and lipophilicity. Substances that are
less permeable can be transported by specialized transport proteins through facilitated
diffusion or active transport. Glucose, for example, is a vital nutrient in pregnancy as it is
one of the primary substrates for fetal growth throughout gestation. It is transported by
facilitated diffusion by glucose transporters (GLUTs) expressed on both the
syncytiotrophoblast and fetal endothelial cells and its transfer is dependent upon a
maternal-fetal concentration gradient, which is discussed in further detail in Chapter 2.
There are also a variety of transporter proteins in the placenta that mediate active
transport, a process that requires the hydrolysis of adenosine triphosphate (ATP)23. For
example, amino acids in the placenta are transferred by active transporters that work
against the concentration gradient, as the levels of amino acids in the fetal circulation is
higher than that of the maternal24. More than 5 amino acid transporters have been
characterized in the human placenta and a majority are a part of the solute carrier (SLC)
family of membrane transport proteins that function through cotransport with sodium25.

Expression of nutrient membrane transporters is altered in the placentas of women
affected by diseases of pregnancy, suggesting that nutrient transfer is related to the
pathophysiology and/or symptoms of these adverse pregnancy outcomes. For example,
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in gestational diabetes mellitus (GDM), there is an increase in glucose and amino acid
transporter expression levels in the placenta and babies born in GDM pregnancies are
often large for gestational age (LGA)26. Thus, the change of placental nutrient transport
leads to pathological fetal growth in utero. GDM has become increasingly prevalent as
major public health concern as it is associated with maternal obesity and the obesity
epidemic has continued to spread worldwide. In fact, an estimated 27% of women of
childbearing age in the United States are obese, resulting in a large population that is at
risk for GDM and LGA infants26. Conversely, in intrauterine growth restriction (IUGR),
which occurs in approximately 5-15% of pregnancies in the United States and Europe,
there is a reduction in the expression of nearly all nutrient transporters throughout the
placenta27. Thus, there is reduced nutrient availability and babies born in IUGR
pregnancies tend to be small for gestational age (SGA) with an associated increased risk
of preterm birth28. In both IUGR and GDM, there are risks for perinatal or postnatal
complications to the mother and baby. Furthermore, being born as either SGA or LGA
leads to the increased risk of developing metabolic and cardiovascular disease later in life.
Therefore, nutrient availability is of critical importance for both short-term and long-term
health. With these far-reaching effects, it is important to better understand the
mechanisms that govern placental nutrient transport. Potential interventions or
therapeutics could be developed to counteract the effects of an abnormal in utero nutrient
environment to prevent potential negative impacts on fetal development.
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Figure 1.6. Mechanisms of cellular transport. Specialized protein transporters
mediate transfer of substances across the cell membrane. In passive diffusion,
molecules freely pass through the cell membrane without energy input based on
characteristics like size, charge, and lipophilicity. In facilitated diffusion, transfer down
a concentration gradient across the membrane is mediated by transmembrane protein
transporters. No energy is required for this process. Finally, active transport is
transporter-mediated passage of molecules against a concentration gradient that
requires ATP or another source of energy. Placental transport falls into these three
main categories.

1.3.2. Xenobiotics and the placenta
While the placenta is instrumental in trafficking nutrients and metabolic waste between the
maternal and fetal circulations, it is also the gatekeeper of passage of xenobiotics between
mother and baby. A xenobiotic is defined as any substance that is foreign to the human
body. In the placenta, xenobiotics of interest include infectious agents, such as viruses
and bacteria, and ingested substances, like pharmaceutical drugs, due to their potential
impact on the health of the developing fetus29. An understanding of how these exogenous
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substances act at the placental maternal-fetal interface is paramount to predicting their
effects on pregnancy success.

A great deal of placental xenobiotic research has centered around placental transmission
of infectious vectors, investigating the effects of both chronic and acute viral infections as
well as bacterial infection. Some microorganisms will present with no adverse fetal
outcomes, while others can result in fetal infection or spontaneous pregnancy loss. The
infections that pose the greatest risk to pregnancy and lead to congenital abnormalities
are referred to as TORCH infections and include Toxoplasmosis, Other (syphilis, varicellazoster, parvovirus B19), Rubella, Cytomegalovirus, and Herpes30. These infections spread
through hematogenous transmission from the maternal circulation through the placenta to
the fetus. Prenatal, perinatal, and postnatal exposure to these microorganisms can lead
to serious congenital defects, such as microcephaly, cardiac abnormalities, and even
stillbirth31. More recently, Zika virus has also been considered to be an emerging
microorganism that falls under the TORCH umbrella with the prevalence of microcephaly
and other congenital abnormalities in babies born to mothers infected with the virus32.
Understanding the placental kinetics of these agents and early diagnosis of disease have
enabled clinical approaches for prevention and treatment.

Placental drug transfer is another field of xenobiotic transport that is of paramount
importance to the developing fetus. A recent study of over 9,000 women in the United
States showed that 97% of women took at least one drug during pregnancy and 30% of
women took at least five medications117. Historically, it was believed that the placenta was
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an impenetrable barrier that prevented passage of drugs to the fetal circulation, but this
has been proven false. Any drug taken by an expecting mother during pregnancy will be
present in the maternal circulation and therefore encounter the placenta, where transport
pharmacokinetics at the placental barrier will dictate fetal exposure. The characteristics of
a drug, such as molecular weight, lipophilicity, and polarity, determine how it is handled
by the placenta. It is believed that drugs with a molecular weight <500 Da can cross the
placenta through passive diffusion, but larger drugs (MW >1000 Da) cannot33. In addition
to passive transfer, there is active transport mediated by membrane transport proteins
expressed on the cells of the placental barrier and also metabolism of drugs by placental
tissue. In particular, a group of proteins in the ABC transporter family have been shown to
play an important role in drug efflux at the placental barrier34. These transporters, many of
which are expressed on other tissues in the human body, recognize a variety of
medications as substrates. In some cases, these proteins protect the fetus from drug
exposure through efflux of drugs back into the maternal circulation. However, there are
relatively few drugs that have been rigorously tested for placental metabolism and
transport, much less for safety to the developing fetus, and thus this remains an area in
need of innovation and further research.

1.4 Pathology of the human placenta
As has been briefly discussed in this introduction, there are a variety of adverse outcomes
relating to the placenta that can occur during pregnancy and pose risks to maternal and
fetal health. The ability to diagnose these conditions early and provide therapeutic
interventions for expecting mothers is severely limited by the lack of understanding of the
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pathophysiology of the disorders. Therefore, there is a need in the field of placental biology
to better understand the underpinnings of these conditions in order to provide better
clinical care to affected mothers and babies. While modern medicine has brought about
marked improvement in clinical care, complications of pregnancy and maternal mortality
remain a public health concern in the United States. In fact, the United States has the
highest rate of women dying of pregnancy-related complications of any developed
country35. This chapter will briefly outline a selection of pathologies of the human placenta
that continue to have a significant impact on maternal and fetal outcomes and health. In
each condition, progress in understanding the etiology of disease has been hampered by
a lack of predictive research platforms. Current in vitro systems cannot recapitulate the
complexity of the uterine or placental environments and animal models do not fully
reconstitute human pathology36. Thus, as this dissertation proposes, there is a need for
novel tools like microphysiological models to study placental pathology.

1.4.1. Preeclampsia
Preeclampsia is a disorder of pregnancy that affects an estimated 2-8% of pregnancies
worldwide and is a significant cause of maternal and neonatal morbidity and mortality37.
In the United States, rates of preeclampsia have risen in recent decades and the obesity
epidemic has in part driven this trend38. It is a systemic condition that presents as a
multitude

of

symptoms,

including

hypertension,

proteinuria,

headaches,

thrombocytopenia, swelling of extremities, and more39. Late in pregnancy, especially if
symptoms are not well-controlled, preeclampsia can result in end-organ damage with
endothelial pathology occurring in the kidneys, liver, and even brain40. The origins and
pathophysiology of preeclampsia are still not well understood. Epidemiological studies
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have established a set of risk factors for the disorder, including primiparity, family history,
obesity, and pre-existing hypertensive conditions41.

Figure 1.7. Spiral artery remodeling. Spiral arteries are uterine vessels located in
the endometrium. During implantation in a normal pregnancy, cytotrophoblasts invade
into the decidua and remodel the spiral arteries to convert them to low resistance
vessels. In an abnormal pregnancy, this process does not proceed correctly and there
is insufficient remodeling of the uterine vasculature. This leads to inadequate placental
perfusion during gestation.

Abnormal placentation in the early stages of pregnancy is the point at which preeclampsia
originates. As discussed in the chapter on implantation in this dissertation, early in
placentation, extravillous trophoblasts invade and remodel the uterine spiral arteries to
convert them to high capacity and low resistance vessels. In preeclampsia, this process
of trophoblast invasion is impaired and the spiral arteries are not properly remodeled,
therefore resulting in poor placental perfusion, as illustrated in Figure 1.742. Spiral artery
remodeling occurs by 20 weeks of gestation and is complete prior to the presence of
clinical signs, making early diagnosis of preeclampsia difficult. Women whose uterine
vasculature has not been properly remodeled will not necessarily experience symptoms
until later in pregnancy.
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Although the link between aberrant trophoblast migration and preeclampsia was
discovered decades ago, the molecular basis of what governs this process is still poorly
understood. As discussed, a variety of risk factors have been identified but a mechanistic
understanding of how preeclampsia develops is still unknown. Recent work has
demonstrated that an abnormal balance of circulating angiogenic and anti-angiogenic
factors, such as soluble fms-like tyrosine kinase 1 (sFlt-1), are pathogenic and may
represent a potential therapeutic target pathway43. This also presents an opportunity for
earlier diagnosis.

1.4.2. Intrauterine growth restriction
Intrauterine growth restriction (IUGR) is defined clinically as birth weight falling under the
10th percentile of predicted weight for gestational age. There are a variety of diseases and
conditions that have been associated with IUGR, yet some cases are idiopathic. For
example, women with chronic diseases like sickle cell anemia, celiac disease, or kidney
disease are more likely to have pregnancies affected by IUGR. Due to the fact IUGR
babies are born SGA, they are predisposed to developing metabolic and cardiovascular
disease in adult life through fetal programming. However, more acutely, IUGR is
associated with severe neurodevelopmental defects and a tenfold increase in infant
mortality18. Diagnosis usually occurs through ultrasound or magnetic resonance imaging.
Once diagnosed, there are few treatments options for pregnant women to pursue. Clinical
recommendations include lifestyle modifications like a healthy diet and increased bedrest.
Women are also encouraged to track fetal movements after diagnosis due to the
heightened risk of fetal demise and stillbirth. However, no therapeutic interventions
currently exist.
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The etiology of IUGR is not well understood but relates to poor placental perfusion and
aberrant nutrient transfer. It sometimes occurs in cases of abnormal placentation like
preeclampsia, placenta accrete, and placenta previa. Placentas from IUGR pregnancies
are often smaller than those of normal pregnancies and contain fewer functional units with
reduced

villous

vasculogenesis44.

Histological

analysis

demonstrates

placental

dysfunction with ischemic and thrombotic lesions as well as widespread inflammation and
areas of necrosis45. Researchers hypothesize that hypoxic insults or ischemia/reperfusion
injury during placental development may result in IUGR pathology, however many
questions remain as to how this dysfunction progresses. Therefore, a more precise
mechanistic understanding of exactly how IUGR develops could result in the discovery of
novel therapeutics to treat this condition beyond just dietary and lifestyle changes in order
to improve fetal outcomes.

1.4.3. Gestational diabetes mellitus
Gestational diabetes mellitus (GDM) affects approximately 9% of pregnancies in the
United States and this rate continues to rise with the increasing prevalence of obesity in
women of childbearing age46. It is clinically defined as impaired glucose tolerance that
begins or is first recognized during pregnancy. Pregnancies affected by GDM are high risk
and can potentially lead to neonatal hypoglycemia, macrosomia, or need for cesarean
delivery47. Pregnancy is associated with decreased insulin insensitivity that results from
circulating placental hormones. A concomitant increase in insulin secretion compensates
for this change and enables glycemic control in normal pregnancies48. In GDM, however,
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an adequate insulin response is not achieved to compensate for this reduced insulin
sensitivity and this leads to maternal hyperglycemia.

Some women who have GDM will simply return to a euglycemic state after delivery. Yet
in some women, clinical studies show there is a heightened risk of developing type 2
diabetes or other metabolic or cardiovascular diseases after a GDM pregnancy47. The
main complication that occurs for the baby is macrosomia, which is defined as birth weight
above the 90th percentile for gestational age. Macrosomia occurs in 12% of normal
pregnancies, but up to 45% of GDM pregnancies49. Perinatal risks exist as injures like
shoulder dystocia or clavicle fracture can occur to the baby during delivery. The most
impactful sequelae of GDM and macrosomia, however, lies in the fetal programming of
adult disease. These LGA infants will have an increased risk of developing diabetes and
cardiovascular disease later in life. With these health risks to both mother and baby, it is
critical that GDM is well-controlled in pregnancy after diagnosis. Early detection is key in
preventing adverse outcomes and guidelines in the United States dictate that pregnant
women be screened for GDM with a glucose tolerance test at 24 to 28 weeks of
pregnancy. Currently, women who are diagnosed with GDM are treated with drugs like
glyburide, metformin, and insulin and counseled for lifestyle modifications with the goal of
tight glycemic control50.

1.4.4. Preterm birth
The average length of human gestation is 40 weeks, or 280 days, from the first day of a
woman’s last menstrual period. Interestingly, only 4% of women deliver at 280 days and
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only 70% deliver within 10 days of the predicted due date51. Preterm birth is defined as
delivery before 37 weeks of gestation. Babies born preterm are vulnerable to a variety of
perinatal complications, including respiratory distress syndrome, anemia, as well as longterm consequences, like asthma and developmental delays. There has been a concerning
trend in the United States in recent years as preterm birth rates have actually risen, despite
advances in modern medical care. Rates had been on the decline from 2007 to 2014, yet
this trend reversed in 2015 has continued to rise in the years since. Currently, almost 1 in
10 pregnancies in the United States results in delivery before 37 weeks of gestation.
Furthermore, significant racial disparities exist, as the rate of preterm birth is 14% in
African American women compared to 9% in white women. Although being born
premature is one of the top causes of infant mortality worldwide, there are very few clinical
approaches to detect and prevent preterm birth in pregnant women. In order to tackle this
issue, there has been increasing attention on research to better understand preterm birth.
For example, the March of Dimes Foundation launched an initiative in 2015 to fund
multidisciplinary prematurity research centers to identify the mechanisms that regulate
term and preterm delivery.

Since preterm birth is poorly understood, it is nearly impossible to predict, prevent, or treat.
Thus, progress needs to be made in elucidating the mechanisms that underlie this
pregnancy outcome. Genetics have been found to be linked to 30-40% of preterm births
and a landmark study in 2017 identified 6 genomic loci that were associated with
gestational duration52. These roles of these genes are associated with maternal nutrition,
vascular control, and uterine function, suggesting these factors may play a role in the
etiology of preterm birth. There is also a great deal of interest in the role of placenta in
21

preterm delivery as it mediates signaling between mother and baby. Histological analysis
of placenta from spontaneous preterm births show vascular malperfusion lesions and
signs of inflammation53. Transcriptomic analysis that compared term and preterm
placentas identified 129 genes that were differentially expressed between the two
conditions54. It is clear from these and other studies that the placenta influences the
progression of preterm birth, but further work is needed better understand this link,
especially in research platforms that can evaluate signaling between mother and fetus.

1.5 Placental research platforms
Ethical and safety concerns prevent in vivo placental research from being conducted in
pregnant women. Potential adverse effects of experimental protocols on maternal or fetal
health preclude a majority of research in pregnant human subjects. In fact, the Food and
Drug Administration (FDA) instated a rule in the 1970’s that excluded women of
childbearing age from clinical trials55. Thus, for decades, drugs have become available on
the market that have never been assessed for efficacy or safety in pregnant women. In
2018, the FDA released a draft guidance that outlined a plan for updating this policy and
including pregnant women in trials that have shown adequate preclinical safety. The
impact of limitations of placental research platforms extends beyond just the field of drug
efficacy and safety. However, due to the lack of in vivo research opportunities, advances
in the field of placental biology have relied upon in vitro and ex vivo platforms as well as
animal models. The benefits and limitations of these commonly employed tools will be
discussed herein.

22

1.5.1 In vitro approaches
The field of placental biology has been hugely dependent on a variety of in vitro platforms.
Over the past few decades, a great deal of research in placentology has focused on
trophoblasts. This work has been carried out in immortalized cell lines as well as primary
cultures. The most widely used cell lines for modeling the trophoblast are BeWo, JAR, and
JEG cells. Each cell has a unique phenotype and thus is selected depending on the topic
of the study of interest. However, as is the case with the use of transformed cell lines in
biomedical research, there are limitations to employing these cell types for trophoblast
research56. Cell lines are a cost-effective and efficient option due to their indefinite
proliferation potential. However, cell lines may not fully recapitulate all biological pathways
present in primary tissues and repeated subculture leads to genotypic and phenotypic
variation. Furthermore, researchers have found that 18-36% of all cell lines used in
biomedical research are misidentified or cross-contaminated57.

Primary cells that isolated directly from tissues and organs provide an alternative to cell
lines. These are regarded as the cell type that are most relevant to in vivo physiology.
Placental biology researchers have developed protocols over the years to isolate cell
types of interest from the whole placenta for experimental work and have employed these
cells in studies that have led to significant progress in the field58,59. However, primary cells
have a limited in vitro life span and often can only be used for a maximum of 3-4 passages.
In particular, primary villous trophoblasts are post-mitotic and do not proliferate, thus
limiting the possible duration of experiments. Additionally, it can be difficult to procure
primary placental cells as it requires proximity to a clinical care setting where placentas
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can be made available after delivery and skilled technologists to perform the isolation
procedure.

More recently, embryonic and induced pluripotent stem cells have been used to study
trophoblast function and differentiation. These present some of the advantages of
physiological relevance of primary cells, without the need for proximity to primary tissues.
Xu et al. first developed a protocol in 2002 using bone morphogenetic protein 4 (BMP4)
to differentiate pluripotent stem cells into cells that express trophoblast-related genes60.
This protocol has been improved by various groups of the years to reduce the expression
of mesoderm markers and improving the purity of the iPSC-derived cells. Horii et al.
employed a two-step BMP4 protocol to differentiate pluripotent stem cells into bipotential
cytotrophoblast cells61. Interestingly, the authors were able to recapitulate the trophoblast
defects of trisomy 21 by differentiating trisomy 21-affected pluripotent stem cells.

1.5.2 Animal models
A great deal of biomedical research, ranging from basic science work to preclinical drug
development, is reliant upon animal models for increasing the understanding of human
physiology and pathophysiology. This in vivo work in a variety of species has led to
significant advances in understanding health and disease as well as the target
identification and validation of novel drugs. Like other fields, placental biology researchers
have employed animal models to advance the understanding of placental development
and function. However, as has been an issue in other areas of biomedicine, the translation
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of findings in these models to human physiology is severely hampered by the existence
of significant interspecies differences15.

There are four classifications of mammalian placentas: hemochorial, epitheliochorial,
endotheliochorial, and syndesmochorial62. The hemochorial human placenta is structurally
and functionally unique compared to those of other mammals. Due to the complexity of
this transient organ, there are several points at which human placentation is distinct to that
of other species – ranging from early implantation and trophoblast invasion to endocrine,
immune, and transport function later in gestation. As such, no other animal perfectly
reconstitutes the process of human placentation. In fact, an entire area of research called
comparative placentation has been devoted to the diversity of mammalian placentas63.
Over the course of decades, the unique range of placental diversity has been documented
across numerous species and remains a biological marvel.

In biomedical research, the most commonly used laboratory animals are mice and rats,
however, placentation in these two species differs considerably from that of humans. The
length of gestation in mice is only 20 days compared to approximately 280 days in
humans. With these differences in gestational period, key steps in placental development
occur on different time scales. Furthermore, rodents have several pups per pregnancy
whereas humans most commonly have singleton pregnancies.

Early in gestation,

decidualization and implantation occur in opposite order in mice compared to humans15.
Structurally, there are stark differences between the placentas of mice and humans. The
human placenta is hemochorial, meaning the maternal blood is in direct contact with the
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chorionic membranes. Mouse placentas are also hemochorial, yet additional trophoblast
cell layers exist between the maternal and fetal circulations and maternal blood is pooled
in the labyrinth, rather than the intervillous space of humans64. As such, the physiology of
the rodent placenta is not necessarily predictive of that of humans. In general, there is no
single animal model that is best for studying human placental physiology16. Instead,
researchers can choose the species that best replicates the aspect of placental function
they aim to study. For example, investigation into the mechanisms underlying spiral artery
remodeling would be best accomplished in an animal that exhibits similar timing and
degree of extravillous

trophoblast invasion and function. However, this may not

necessarily be the same species that is chosen for studies of transplacental transport.

1.5.3 Ex vivo placental perfusion
Another technique employed for studying the human placenta utilizes the ex vivo placental
perfusion model, which was first developed in the 1970’s65. In particular, the dually
perfused placental cotyledon is the gold standard for placental transport studies and has
been widely used for investigation of placental metabolism66. In this system, following
delivery, the placenta is obtained and immediately perfused with buffer solution to wash
out fetal blood. A single cotyledon is then isolated and cannulated for perfusion, which can
be conducted in either a single pass or recirculating fashion67. Perfusion protocols differ
at individual research laboratories, but a majority of maternal-fetal transport experiments
are conducted over a period of 2 to 6 hours. This platform has been used to investigate
the placental transport kinetics of both endogenous and exogeneous substrates, including
nutrients, drugs, viruses, and hormones68-70.
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Despite the utility of this platform, widespread adoption of the approach is limited by the
requirement for experienced technicians and an intricate, laborious experimental setup.
According to a retrospective study conducted by Mathiesen et al., in a one-year period
only 15% of placentas received by research laboratories experienced in the technique
were successfully perfused71. While 92% of tested placentas passed the point of
cannulation, failure most often occurred subsequently when leaks from the fetal circulation
were detected precluding the ability to carry out studies of placental transport. This low
success rate is compounded by the challenges in obtaining tissue and the limited window
that the organ remains viable after birth. Therefore, the combination of tissue scarcity and
technical challenges in experimental setup make ex vivo models difficult to be widely used.

1.6 Organ-on-a-chip technology
Over the last two decades, there has been considerable effort to apply microfabrication
techniques initially pioneered by the semiconductor industry to create a new class of in
vitro cell culture models. The precision of these engineering approaches enables
development of miniaturized compartmentalized platforms that offer the unprecedented
ability to culture cells in a physiologically relevant three-dimensional arrangement and
control the cellular microenvironment with a high degree of spatiotemporal resolution.
These efforts led to the development of the field of organ-on-a-chip technology, which was
pioneered in 2010 with the development of a microphysiological lung model by Huh et al
that effectively combined culture of human cells and microengineering principles to
reverse engineer the salient features of the lung in vitro72. In this platform, alveolar
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epithelial cells and lung capillary endothelial cells were cultured in apposition on a porous
membrane to recapitulate the native alveolar architecture found in the human lung. The
alveolar epithelial cells were cultured at the air-liquid interface under cyclic stretch and
endothelial cells were maintained under dynamic conditions, thus mimicking the
physiological microenvironmental cues of breathing motions and hemodynamic flow,
respectively. This system was then applied to create a disease-specific model of bacterial
infection that recapitulated immune response and demonstrated immune cell trafficking
on-chip. The field of organ-on-a-chip technology has exploded in recent years with the
design of a myriad of other microphysiological organ models, with systems being
developed to model the intestine, brain, kidney, and many more73-77. It provides the
exceptional ability for researchers to probe the native microarchitecture and dynamic
microenvironment of human tissues and organs. The potential of this technology has
resulted in interest in both academia and industry. The National Institutes of Health
National Center for Advancing Translational Sciences (NCATS) started the Tissue Chip
program in 2012, allotting millions of dollars for organ-on-a-chip research at universities
nationwide. The next phase of this program was announced in 2017 in support of
development of tissue models to improve preclinical drug studies.

The value of this technology also led to the formation of various start-up companies in the
space, including Emulate Bio, Mimetas, and CNBio. Each company has a unique
approach to commercialization of organ-on-a-chip systems, though all aim to develop
systems for widespread adoption of their platforms in biomedical research facilities. A
majority of current approaches for fabrication of organ-on-a-chip devices require complex
microfabrication technique, so often require a skilled user. Thus, there is a great deal of
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value in the products these start-up companies are creating in providing a greater number
of researchers with access to this technology. Additionally, there has been increasing
interest by large pharmaceutical companies in employing microphysiological systems in
drug development. Over 60% of investigational drugs fail in human clinical trials and this
is largely due to the lack of predictive value of current in vitro cell culture approaches and
in vivo animal models employed in pharmaceutical research. The ability of organ chips to
utilize human cells to model complex biological processes may offer an improved
approach for testing drug toxicity and efficacy. This has inspired biopharma corporations
like AstraZeneca and GlaxoSmithKline to incorporate work on microphysiological systems
into their research and development units.

Motivated by the utility of organ-on-a-chip systems in advancing biomedical research, we
set out to leverage these microengineering approaches to create microphysiological in
vitro platforms to study the human placenta (Figure 1.8A-B). Despite the aforementioned
growth in development of organ-on-a-chip platforms to study human tissues and organs,
very few groups have focused on applying this technology to reproductive medicine78. The
Woodruff group at Northwestern University developed a series of organ-on-a-chip devices
that model several tissues of the human female reproductive tract and recapitulate the 28day menstrual cycle79. This remarkable system could be applied to drug testing and
disease modeling in various women’s health applications, however, it does not include the
human placenta. Thus, it cannot adequately model the physiology and pathophysiology of
human pregnancy. With this opportunity and the major need for innovation and progress
in the field of placental biology, we have worked to create two microphysiological models:
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one that reconstitutes the human placental barrier and one that recapitulates the
physiological process of implantation.

Figure 1.8. Microengineered platforms to study the human placenta. A. A
microphysiological model of the human placental barrier. B. A microengineered
system to study human implantation.

1.7 Outline of Dissertation Chapters
This dissertation discusses the design and application of microengineering technologies
to study the human placenta. In Chapter 2, the initial development and characterization
of a microengineered in vitro model of the human placental barrier, or placenta-on-a-chip,
is described. This work outlines the design of a multilayered microfluidic device that
recapitulates the microarchitecture and dynamic environment of the human placental
barrier. It describes the use of the placenta-on-a-chip to investigate maternal-fetal glucose
transfer and validates the on-chip results to existing in vivo and ex vivo data. In Chapter
3, the placenta-on-a-chip system is used to study the effects of hemodynamics on
placental barrier function. Specifically, it examines the impact of fluid shear stress on
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cytotrophoblast syncytialization. In Chapter 4, the microengineered model of the human
placental barrier is employed to analyze transfer of maternally administered drugs to the
fetal compartment. The transport kinetics of fluorescently labeled heparin and glyburide
are evaluated on-chip. In Chapter 5, the microengineering strategies leveraged to study
the human placental barrier are applied to develop a platform to study human implantation
and extravillous trophoblast migration. It describes a microphysiological system that
reconstitutes the uterine stroma, maternal vasculature, and invading EVTs. Finally,
Chapter 6 summarizes conclusions from this dissertation work and outlines future
directions for utilizing microengineering approaches to study the human placenta.
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CHAPTER 2. Development of a Microphysiological Model of the
Human Placental Barrier

This chapter is a modified version of “A microphysiological model of the human placental
barrier” published in Lab on a Chip by Blundell et al. in 2016.

Abstract
During human pregnancy, the fetal circulation is separated from maternal blood in the
placenta by two cell layers – the fetal capillary endothelium and placental trophoblast.
This placental barrier plays an essential role in fetal development and health by tightly
regulating the exchange of endogenous and exogenous materials between the mother
and the fetus. Here we present a microengineered device that provides a novel platform
to mimic the structural and functional complexity of this specialized tissue in vitro. Our
model is created in a multilayered microfluidic system that enables co-culture of human
trophoblast cells and human fetal endothelial cells in a physiologically relevant spatial
arrangement to replicate the characteristic architecture of the human placental barrier.
We have engineered this co-culture model to induce progressive fusion of trophoblast
cells and to form a syncytialized epithelium that resembles the syncytiotrophoblast in vivo.
Our system also allows the cultured trophoblasts to form dense microvilli under dynamic
flow conditions and to reconstitute expression and physiological localization of membrane
transport proteins, such as glucose transporters (GLUTs), critical to the barrier function of
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the placenta. To provide a proof-of-principle for using this microdevice to recapitulate
native function of the placental barrier, we demonstrated physiological transport of glucose
across the microengineered maternal-fetal interface. Importantly, the rate of maternal-tofetal glucose transfer in this system closely approximated that measured in ex vivo
perfused human placentas. Our “placenta-on-a-chip” platform represents an important
advance in the development of new technologies to model and study the physiological
complexity of the human placenta for a wide variety of applications.

2.1. Introduction
The placenta is a highly specialized organ in the human body that plays an integral role in
the development and maintenance of pregnancy1,80. As evidenced by the recent launching
of the Human Placenta Project by the US National Institutes of Health, the current dearth
of knowledge about the human placenta is providing an impetus to improve our ability to
probe and understand the inner workings of this vital organ.

Specifically, collective

research efforts emerging in this area focus on developing new technologies to examine
and monitor human-specific placental structure and function during health and disease81.
These studies are further justified by the poor physiological relevance and predictive
power of existing animal models that have proven problematic for the study of the human
placenta15,82.
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Motivated by these unmet challenges and emerging opportunities in reproductive biology
and medicine, we have developed a microengineered cell culture system that enables a
new approach to modeling the salient features of the human placenta (Figure 2.1A,B).
The primary role of the placenta is to mediate the exchange of various endogenous and
exogenous substances between the mother and fetus during pregnancy2,33. Central to
this critical organ function is a multilayered membranous structure that consists of the
syncytiotrophoblast and the fetal capillary endothelium, separated by a thin interstitium
(Figure 2.1C). This specialized barrier, which separates the maternal intervillous space
and fetal circulation, is responsible for regulating the rate and selectivity of placental
transport.

Aberrant changes in its structure and function are implicated in various

complications of pregnancy, such as preeclampsia and intrauterine growth restriction83,84.

Figure 2.1. A. Schematic of a human fetus and placenta within the uterine cavity. The
placenta is anchored to the uterine wall and connected to the developing fetus via the
umbilical cord. B. Cross-sectional view of the placenta illustrates the placental cotyledons.
Each cotyledon consists of a stem chorionic villus and its branches. These villi are in direct
contact with maternal blood in the intervillous space. C. The maternal intervillous space is
separated from the lumen of the fetal capillary by the maternal-fetal interface composed of
the syncytiotrophoblast, basal lamina, and villous endothelial cells. D. The threedimensional microarchitecture of the placental barrier is reconstituted within our
microengineered system.
The placenta-on-a-chip consists of upper and lower
microchannels separated by a thin, semipermeable membrane. Trophoblast cells are
cultured in the upper microchannel on the apical side of the membrane, and villous
endothelial cells are grown in the lower microchannel on the basal side of the membrane.
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Our microsystem provides a novel platform to emulate this essential unit of the placenta
by allowing human placental cells to grow and organize into a multilayered living tissue
that replicates the native architecture of the maternal-fetal interface. Specifically, this
model is a compartmentalized microfluidic system consisting of two closely apposed
microchannels to enable culture of human trophoblasts and human placental villous
endothelial cells on opposite sides of a thin semipermeable membrane under dynamic
flow conditions (Figure 2.1D). The design of this device also makes it possible to engineer
the soluble microenvironment of the maternal compartment to induce syncytialization of
the trophoblast cells and to reproduce their differentiated morphological and biochemical
phenotypes. We show progressive fusion of the cultured trophoblast cells and their
increased production of human chorionic gonadotropin during the course of
syncytialization induced by the activation of the protein kinase A pathway.

To further demonstrate the potential of this biomimetic microengineering approach, we
present our “placenta-on-a-chip” system as a promising alternative to existing models for
the study of physiological transport function of the human placenta. Current research on
placental transport relies heavily on in vitro techniques based on Transwell cell culture
inserts that provide a polarized environment conducive to barrier formation66.

This

traditional approach, however, has been used predominantly for establishing monoculture
of trophoblast cells to study their transport function. Consequently, existing Transwell
models do not mimic the multi-layered structure of the placental barrier, failing to
recapitulate endothelial contribution to physiological barrier function85. Furthermore, static
culture conditions in these models do not reconstitute the dynamic flow environment of the
placenta in vivo that has been shown to influence cellular phenotypes in the placental
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barrier86.

As an alternative approach, researchers utilize ex vivo models involving

controlled perfusion of the whole human placenta87. Although this technique has gained
widespread acceptance in placental transport studies, significant challenges remain due
to the requirement for human specimens, the limited amount of time that tissue remains
viable, and the inconsistent results produced by these models71. The whole organ strategy
also makes high-resolution analysis at the cellular and tissue levels difficult, which is often
required for a mechanistic understanding of placental transport. As a new approach to
address the shortcomings of these existing techniques, we demonstrate the feasibility of
leveraging our microengineered platform to model physiological biomolecular transport
across the maternal-fetal interface. Using glucose as a model substance, we show that
our microengineered placental barrier is capable of mediating net directional molecular
transport from the maternal to fetal compartments. Our data also reveal the advantage of
this biomimetic microsystem over Transwell inserts for accurately predicting the
physiological rate of glucose transport in the human placenta.

2.2. Materials and Methods
2.2.1. Cell culture
The BeWo b30 human trophoblast cell line88 was obtained from Dr. Nicholas Illsley of
Hackensack University Medical Center and was cultured in DMEM/F-12K medium (GE
Healthcare) containing 10% fetal bovine serum (FBS), 1% L-glutamine, and 1%
penicillin/streptomycin (Gibco).

Human primary placental villous endothelial cells
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(HPVECs) were isolated from term placentas as described previously89 and maintained in
EGM-2 medium containing 2% FBS (Lonza).

For static Transwell cell culture studies, Transwell inserts (24-well plate; pore size = 0.4
µm; surface area = 0.33 cm2) were coated with human fibronectin solution (0.1 mg/ml in
PBS). For cell seeding, the insert was first inverted, and a drop of HPVEC suspension
(50,000 cells/insert) was placed on the basal surface of the insert membrane. The seeded
insert was then placed in a cell culture incubator for 1 hour for cell attachment. Following
HPVEC adhesion, the insert was washed and placed back in the well plate, and the basal
compartment was filled with endothelial media. Subsequently, the apical chamber of the
insert was filled with a BeWo cell suspension (50,000 cells/insert), incubated for 1 hour,
and washed to seed the upper side of the membrane with trophoblast cells.

2.2.2. Microdevice fabrication
The upper and lower layers of the microdevice were fabricated using standard soft
lithography techniques (Figure 2.2A-B). Briefly, poly(dimethylsiloxane) (PDMS) (Sylgard,
Dow Corning) base was mixed with curing agent at a weight ratio of 10:1 and degassed
to remove air bubbles.

The mixture was then cast on a silicon master containing

photolithographically prepared microchannel features made of SU-8 (MicroChem). The
microchannel dimensions were 1 mm (width) x 1.5 cm (length) x 135 μm (height). A biopsy
punch was used to create 1 mm-diameter holes through the upper PDMS slab to gain
fluidic access to the upper and lower microchannels.

37

To assemble the device, the two PDMS layers were bonded to a semipermeable
polycarbonate membrane containing 1 μm pores (GE Healthcare) using adhesive PDMS
mortar90. To create this layer, PDMS precursor was mixed with curing agent at a weight
ratio of 10:3 and spin-coated on a 100 mm Petri dish at 2500 rpm for 5 minutes.
Subsequently, both the upper and lower microdevice layers were gently placed on the
dish to transfer the spin-coated mortar film onto the surfaces of the PDMS slabs containing
the microchannel features. This step was followed by bonding of the polycarbonate
membrane to the upper PDMS slab. These two layers were then aligned and attached to
the lower PDMS slab, and cured at room temperature overnight to ensure complete
bonding.

Figure 2.2. Fabrication of the placenta-on-a-chip microdevice. A. Schematic of
device bonding. Two PDMS layers containing a hollow microchannel are bonded
with a semipermeable membrane (shown in tan) sandwiched between. B. A
scanning electron microscope image of the cross-section of the fully bonded device
illustrates the dual channel system of the placenta-on-a-chip. The upper
microchannel represents the maternal circulation and the lower microchannel
represents the fetal circulation. A higher magnification image depicts the porosity of
the intervening polymeric membrane.
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2.2.3. Microfluidic cell culture
The assembled microdevice was first sterilized using UV irradiation. Following sterilization,
the surface of the intervening porous membrane was coated with extracellular matrix
(ECM) by filling and incubating the microchannels with a human fibronectin solution (0.1
mg/ml in PBS) at 37°C for at least 4 hours. The channels were then rinsed with PBS to
remove the ECM solution prior to cell seeding.

To form the fetal endothelium, we

introduced a suspension of trypsinized HPVECs (4 x 106 cells/ml) into the lower
microchannel and immediately inverted the device to allow the cells to settle to the original
lower side of the porous membrane.

Subsequently, the seeded microdevice was

incubated at 37C for 1 hour to enable cell attachment and spreading. During this period,
the inlet and outlet access ports were blocked to prevent unwanted convective motion of
culture medium in the microchannels. Once attachment of HPVECs was confirmed, the
device was flipped back, and the upper microchannel was seeded with BeWo cells
suspended in DMEM/F-12K at a concentration of 4 x 106 cells/ml. After incubation at 37C
for 1 hour, the microdevice was connected to syringe pumps that generated continuous
flow of culture media in the upper and lower microchannels at a volumetric flow rate of
100 μL/hr.

2.2.4. Analysis of intercellular junctions
In order to assess the formation of intercellular junctions, the trophoblast cells and
HPVECs were fixed in 4% paraformaldehyde (PFA) for 15 minutes, permeabilized in
0.25% Triton X-100 for 10 minutes, and then incubated in 2% bovine serum albumin (BSA)
for 1 hour. All steps were performed at room temperature. The trophoblast cells and
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HPVECs were incubated with anti-E-cadherin (Life Technologies) and anti-VE-cadherin
antibodies (Cell Signaling Technologies), respectively. These primary antibodies were
diluted in 2% BSA and incubated in the microdevice for 1 hour at room temperature. Next,
the samples were thoroughly washed with PBS.

Secondary antibodies (Life

Technologies) were diluted in 2% BSA, incubated for 45 minutes at room temperature,
and then washed with PBS. Nuclei were labeled using DAPI subsequent to the secondary
antibody incubation. Following staining, the membrane was carefully removed from the
microdevice and mounted onto a coverslip. Images were acquired using an inverted
microscope (Zeiss Axio Observer) and a confocal laser-scanning microscope (Leica TCS
SP8). Image processing and three-dimensional rendering were carried out using Volocity
(PerkinElmer).

2.2.5. Analysis of microvilli formation
Following 72 hours of culture, trophoblast cells grown in Transwell and microfluidic devices
were fixed, permeabilized, and incubated with 2% BSA as described above. Next, the
samples were stained with Alexa 488-conjugated phalloidin (Life Technologies) for 30
minutes at room temperature and washed to visualize F-actin in the microvilli. The cell
nuclei were counterstained with DAPI. A confocal laser-scanning microscope (Leica TCS
SP8) was used to acquire Z-stack images. For quantification of relative fluorescence, Zstack data were converted to a maximum intensity projection image and manual
thresholding was performed in FIJI to isolate fluorescent pixels18. Histogram counting
was used to determine the relative amount of actin fluorescence in static and dynamic
conditions.
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2.2.6. Trophoblast syncytialization
Following formation of a confluent epithelial monolayer on the membrane surface in the
upper microchannel, we treated the apical side of the epithelium with forskolin to activate
the protein kinase A pathway in the cultured trophoblasts. A stock solution of forskolin
(Sigma; 5 mg/mL in DMSO) was diluted with F-12K medium to a final concentration of 50
uM and perfused through the upper microchannel. After 72 hours of forskolin treatment,
the trophoblast cells were fixed in 4% PFA, permeabilized in Triton-X 100, and then
incubated with 2% BSA in PBS for immunofluorescence staining. To analyze changes in
junctional protein expression, the samples were incubated with anti-E-cadherin antibody
(Life Technologies) in 2% BSA, followed by secondary antibody and DAPI. Additionally,
media perfusate was collected at 48, 72, and 96 hours from both untreated and forskolintreated devices.

The collected samples were analyzed using a human chorionic

gonadotropin beta (β-hCG) ELISA kit (Abcam) to quantify the levels of β-hCG produced
by the trophoblast population at each time point.

2.2.7. Measurement of barrier permeability after syncytialization
Barrier function of the syncytialized epithelium was assessed by measuring the transport
of 3 kDa fluorescein isothiocyanate-dextran (FITC-dextran; Life Technologies) between
the maternal and fetal compartments. FITC-dextran (0.1 mg/mL in DMEM/F-12K media)
was introduced to the upper maternal microchannel and perfused for 3 hours. The media
perfusate was collected from both microchannels during this period and the fluorescence
intensity of the collected samples was quantified using a microplate reader (Tecan). The
41

amount of dextran transport was assessed based on the mean fluorescence intensity in
the outflow from the lower fetal microchannel.

2.2.8. Visualization of cell membrane transporters
After 3 days of microfluidic culture, cells were processed for immunofluorescence imaging
as described above in order to evaluate the presence and spatial distribution of glucose
transporters in the microengineered placental barrier. Briefly, cells were fixed on-chip in
4% PFA, permeabilized in Triton-X 100, and incubated in 2% BSA in PBS. The samples
were then incubated with mouse anti-glucose transporter 1 antibody (Abcam), followed by
secondary antibody (Life Technologies). Images were acquired using a confocal laserscanning microscope (Leica), and image processing was carried out using Volocity
software (PerkinElmer). Assessment of transporter membrane localization was performed
using FIJI91. The apical and basal membranes were manually segmented in 10
representative images, and the mean fluorescence intensity was measured in each image.
These values were adjusted for background fluorescence.

2.2.9. Analysis of glucose transport
To analyze glucose transport across the maternal-fetal interface, the maternal
compartment was perfused with culture medium containing 10 mM glucose.

This

increased glucose concentration was generated by adding D-glucose (Gibco) to F-12K
medium. Media on the fetal side contained 5.5 mM of glucose during perfusion. Outflow
from the maternal and fetal microchannels was collected over a period of 2 hours and
analyzed by a glucose meter (Accu-Chek Aviva) to measure glucose concentration. These
42

studies were carried out to measure the rate of transport across three types of barriers:
(1) a bare membrane in a cell-free device, (2) a monolayer of BeWo cells without the
endothelium, and (3) an epithelial-endothelial barrier formed by co-culture of BeWo cells
and HPVECs. For each group, barrier function was quantified by the percent increase in
fetal glucose concentration over the period of perfusion. Additionally, the percent rate of
transfer was calculated for the co-culture model using the following equation previously
described in placental transport studies92, % rate of transfer where and denote changes
in glucose concentration in the fetal and maternal compartments during perfusion,
respectively. This value was compared to the percent rate of transfer previously measured
in the human placenta to investigate the physiological relevance of our model.

To measure glucose transport in Transwell, the apical and basal chambers were filled with
200 μL of epithelial media containing 10 mM glucose and 500 μL of endothelial media with
5.5 mM glucose, respectively. A 50 μL sample was taken from each chamber every 30
minutes over the course of transport experiments. The concentration of glucose in the
samples was measured using a handheld glucose meter (Accu-Chek Aviva). The percent
rate of transfer was calculated as described above.

2.2.10. Statistical Analysis
Results are reported as mean ± S.E.M. Statistical significance was assessed using a twotailed Student’s t-test or analysis of variance (ANOVA). Each experiment was repeated
at least three times.
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2.3. Results and Discussion
2.3.1. Reconstituting the microarchitecture of the human placental
barrier
The function of the maternal-fetal interface as a mediator of placental transport is imparted
primarily by its multilayered physical structure, characterized by the trophoblast epithelium
and the fetal endothelium held in close apposition. Our microengineered system made it
possible to replicate this critical microarchitecture of the placental barrier by permitting
compartmentalization of its two key cell types in the maternal and fetal circulations. The
trophoblast and endothelial cell populations introduced into the microchannels established
firm adhesion to the ECM-coated membrane and began to spread within a few hours of
cell seeding. During perfusion culture, these cells proliferated in a continuous manner to
form fully confluent monolayers in both the upper and lower chambers, which covered the
entire surface of the membrane within 24 hours of initial cell seeding. The resulting bilayer tissue closely resembled the trophoblast-endothelial interface of the chorionic villus
in vivo (Figure 2.3A,B). Despite porosity of the interstitial membrane, we did not observe
cell transmigration between the microchannels, presumably due to the small size of the
membrane pores (1 μm).

Under perfusion culture conditions, the microengineered

placental barrier was maintained without a significant loss of cell viability for prolonged
periods (> 1 week).
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Next, we evaluated the formation of cell-cell junctions to assess structural integrity of the
barrier.

A specific focus of this analysis was on the visualization of VE-cadherin

expression in the fetal endothelium and E-cadherin in the trophoblast cells.
Immunofluorescence imaging of the bilayer tissue cultured for 3 days clearly showed a
network of continuous and well-defined junctional complexes throughout both the
trophoblast and endothelial layers (Figure 2.3C,D).

Importantly, expression of the

junctional proteins was found to be uniform across the entire cell culture membrane,
showing no indication of localized regions with immature junctions. Considering that
intercellular adhesion plays an essential role in placental transport in vivo, these results
together demonstrate the capability of our model to recapitulate not only the relative spatial
arrangement of the maternal and fetal tissue in the placental barrier but also the structural
integrity necessary for its function.

Microfluorimetric analysis of the placental barrier in our device also revealed evidence of
extracellular matrix deposition by trophoblast cells. In the human placenta, laminin is a
critical component of the trophoblast basement membrane in the chorionic villus that
contributes to barrier integrity93. Confocal microscopy of the trophoblast cells cultured in
our device for 6 days showed extensive extracellular deposition of laminin (Figure 2.3E).
Moreover, this deposition was localized to the basal side of the cells, forming a thin layer
of laminin between the epithelium and underlying semipermeable membrane (Figure
2.3F), which was reminiscent of the basal lamina in vivo.
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Figure 2.3. Characterization of the microengineered placental barrier. A. Threedimensional rendering of the microengineered placental barrier. The trophoblast and
endothelial cell populations are stained for E-cadherin (red) and VE-cadherin (green),
respectively. Nuclei are shown in blue. Scale bar: 30 μm. B. Cross-sectional view
of the same microengineered barrier. Scale bar: 30 μm. C. The trophoblast cells
form a continuous network of epithelial adherens junctions (E-cadherin, red). Nuclei
are stained with DAPI (blue). Scale bar: 20 μm. D. The placental villous endothelium
also displays intact cell-cell junctions (VE-cadherin, red). Green and blue show actin
and nuclear staining, respectively. Scale bar: 20 μm. E. The trophoblast cells
produce laminin (green) during culture in our microdevice. The image shows cells
on Day 6. Scale bar: 30 μm. F. Cross-sectional view of laminin deposition. Laminin
is stained green, and trophoblast nuclei are labeled in blue. The location of the cell
culture membrane is indicated by the dotted line. Scale bar: 10 μm.

2.3.2. Microvilli formation in the microengineered placental barrier
Another vital structural feature of the placental barrier is the membrane protrusions on the
apical surface of trophoblasts facing the maternal intervillous space. These microvilli
increase the overall surface area available for placental transport, enabling highly efficient
exchange of nutrients and waste products between the mother and the fetus2.

The

microvillous surface also contains key molecular transporters, as well as hormone
receptors that influence cellular function. Our microfluidic device allowed the cultured
trophoblast cells to recapitulate this critical phenotype.
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Figure 2.4. Microvilli formation. A. BeWo cells cultured under dynamic flow
conditions in the placenta-on-a-chip show widespread microvilli formation on the
apical cell surface. Scale bar: 15 μm. B. Three-dimensional rendering of microvilli
on the surface of BeWo cells in the placenta-on-a-chip. Scale: 20 μm. C. Microvilli in
BeWo cells cultured in Transwell appear finer and significantly less abundant. Scale:
15 μm. D. Quantification of relative fluorescence of microvilli F-actin (green) in static
and dynamic culture conditions. Cell nuclei were counterstained with DAPI (blue).
The intensity of fluorescence generated by microvilli was increased substantially
when the trophoblast cells were grown under flow conditions in the placenta-on-achip, as compared to static Transwell culture (****, p<0.0001).

As illustrated in Figures. 2.4A and 2.4B, the apical surface of the trophoblasts cultured in
the maternal chamber for 3 days was covered with a dense layer of microvilli that appeared
as fine hair-like protrusions in the fluorescence micrographs.

Although cell-to-cell

variability was observed in the extent of microvilli formation, this morphological
differentiation was evident in the vast majority of the cells. In contrast, the trophoblast
cells grown in Transwell for the same period exhibited reduced expression of microvilli
(Figure 2.4C-D). Image analysis of these cells showed a smaller number of microvilli per
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cell, as well as marked morphological alterations characterized by decreased villus length
and thickness.

This significant difference may be attributed to the effect of fluid

mechanical forces that have recently been shown to trigger microvilli formation in
trophoblast cells86. Continuous flow of culture medium in the maternal chamber of our
microdevice generates fluid shear stress that approximates the level of hemodynamic
shear stress in the intervillous space86,94. Presumably, this physiological biomechanical
cue stimulates the trophoblasts to form microvilli, whereas static culture conditions in
Transwell inserts fail to provide the dynamic microenvironment required for this process.
Considering that the microvilli serve as a key regulator of placental transport, these
observations illustrate that our system is advantageous over traditional in vitro models not
only for reproducing the structural phenotype of the placental barrier but also for mimicking
its physiological barrier function.

2.3.3. Syncytialization of the microengineered placental barrier
With the progression of pregnancy, cytotrophoblast cells covering the chorionic villi of the
human placenta differentiate and fuse to form a multinucleated syncytiotrophoblast (Figure
2.5A). This terminally differentiated syncytium forms the continuous outer lining of the
chorionic villi and comes in direct contact with maternal blood in the intervillous space.
This process of syncytialization is a hallmark of placentation and plays a central role in
physiological function of the placental barrier as a key regulator of material exchange
between the maternal and fetal circulations95. While the underlying molecular pathways
of syncytialization are not fully understood, studies have shown that activation of adenylate
cyclase, which is the regulatory subunit of protein kinase A, by 3’,5’-cyclic monophosphate
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(cAMP) or forskolin induces BeWo cells and primary villous cytotrophoblast cells to fuse
and acquire differentiated phenotypes of the syncytiotrophoblast96,97.

Based on these previous findings, we engineered the soluble microenvironment of
trophoblast cells using forskolin-supplemented media to induce syncytialization. When
the BeWo cells in the maternal compartment were exposed to forskolin, they began to
undergo cell-cell fusion as illustrated by nuclear aggregation that was evident at 72 hours
of forskolin treatment (Figure 2.5B). This response occurred in approximately 50% of the
BeWo population and did not exert deleterious effects on cell viability. Concurrent to the
fusion of trophoblast cells was a loss of epithelial cell-cell junctions. As shown in Figure
2.5B, microscopic inspection of the trophoblasts showed significant downregulation of Ecadherin throughout the epithelial layer. Interestingly, this reduced expression of junctional
proteins did not compromise the structural integrity of the barrier. On the contrary,
syncytialization in our model led to improved barrier function.

When we measured

paracellular permeability using FITC-dextran, the amount of dextran transport across the
barrier decreased over the course of forskolin exposure (Figure 2.5C).

These

observations closely match characteristic alterations in the morphology and barrier
function of BeWo cells during their acquisition of syncytiotrophoblast-like phenotypes98,
indicating successful syncytialization of the trophoblast epithelium in our model.

One of the most important functional consequences of trophoblast syncytialization in the
human placenta is the production of hormones that play a crucial role in the progression
of both placental and fetal development99. As a representative example of a placental
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hormone, human chorionic gonadotropin (hCG) is secreted by the syncytiotrophoblast and
serves as a biochemical marker of in vitro trophoblast differentiation. Therefore, we
sought to measure the production of the β subunit of hCG in the maternal compartment of
our model as a way to quantitatively examine syncytialization. In the absence of forskolin,
analysis of maternal outflow yielded no d etectable β-hCG (Figure 2.5D). In contrast,
administration of forskolin triggered production of hCG by trophoblast cells within 48 hours,
and the hormone levels continued to increase over the course of 96 hours of forskolin
treatment (Figure 2.5D). Interestingly, the extent of increase was substantially greater in
the first 48 hours, implying positive feedback control of cell differentiation during the initial
period of stimulation. This may be explained by the previous discovery that hCG produced
by differentiated trophoblast cells activates adenylyl cyclase to increase intracellular cAMP
and thus to further promote trophoblast differentiation100. Taken together, these results
demonstrate that our placenta-on-a-chip platform enables both morphological and
functional differentiation of trophoblast cells to reconstitute the syncytium of the placental
barrier.
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Figure 2.5. Forskolin-induced cell fusion. A. In the human placenta,
cytotrophoblast cells in early gestation go through a process of cell fusion to form
a multinucleated syncytiotrophoblast. The resulting syncytium makes up the outer
lining of the chorionic villi that comes into contact with maternal blood in the
intervillous space. B. The BeWo cells cultured in our model exhibit high levels of
E-cadherin (red) expression prior to forskolin treatment (left). Continuous
epithelial exposure to forskolin over 72 hours induces trophoblasts to undergo cellcell fusion, leading to nuclear aggregation and deceased expression of epithelial
junctions. C. During forskolin-induced syncytialization, the permeability of the
microengineered barrier to dextran decreases over time. (*, p<0.05; a.u.
represents arbitrary unit), as well as between 48h and 72h (**, p<0.01). D. The
BeWo cells produce increasing levels of β-human chorionic gonadotropin (β-HCG)
over 120 hours of forskolin treatment (red bars). Hormone secretion by untreated
cells is negligible.
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2.3.4. Glucose transport across the microengineered placental barrier
Glucose from the maternal circulation is a primary source of energy for fetal growth and
development during pregnancy. The maternal-to-fetal transport of glucose across the
placental barrier is mediated by facilitated diffusion via a family of membrane-bound
glucose transporters (GLUTs)

101,102

.

GLUT1 is the most abundant type of glucose

transporter in the human placenta and is found in the syncytium of the placental barrier.
Its expression has been shown to increase over the second half of pregnancy to meet the
increased rate of fetal growth103. While GLUT1 transporters are expressed in both the
apical and basolateral surfaces of the syncytiotrophoblast layer, studies have revealed

Figure 2.6. On-chip glucose transport. A. The syncytial epithelium in our model
expresses high levels of GLUT1 transporters (red). Blue shows DAPI staining. Scale
bar: 10 μm. B. This cross-sectional view of the trophoblasts shows the asymmetric
localization of GLUT1 transporters to the apical membrane. Scale bar: 5 μm. C.
Immunofluorescence staining of GLUT1 on the apical side is substantially stronger
than that on the basal side (****, p<0.0001). a.u. represents arbitrary unit. D. A
concentration gradient of glucose (green dots) is generated across the
microengineered placental barrier to drive glucose transport from the maternal to fetal
compartments. E. Percent increase in fetal glucose concentration for the bare
membrane, trophoblast monoculture, and co-culture conditions (*, p<0.05). F. The
percent rate of glucose transfer in the placenta-on-a-chip device is similar to that
measured in the perfused ex vivo placenta. The in vitro placental barrier formed in
Transwell fails to reconstitute the physiological glucose transport rates.
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their asymmetric localization, with a greater proportion located on the apical microvillous
membrane facing the maternal intervillous space104. Our model recapitulates this pattern
of GLUT1 expression. Immunofluorescence analysis demonstrated robust expression of
GLUT1 transporters in the population of differentiated trophoblast cells comprising the
microengineered syncytium (Figure 2.6A). More importantly, there was increased GLUT1
expression on the apical side of the epithelium, resembling the native spatial distribution
of the transporter (Figure 2.6B-C).

Based on this evidence of transporter expression and localization, we then carried out
quantitative analysis of glucose transport in the placenta-on-a-chip system. In this study,
facilitated diffusion of glucose from the maternal to fetal compartment was induced by
creating a concentration gradient across the microengineered tissue interface (Figure
2.6D). As a control condition, we first evaluated glucose transport in a model consisting
of the upper and lower microchannels separated by a bare membrane. Measurements
taken from this acellular system were used to establish the baseline permeability of the
porous membrane to maternal glucose. To assess the contribution of the epithelium to
barrier function, another control group was generated by similar devices used for
monoculture of trophoblasts in the maternal compartment. As shown in Fig. 6E, the
presence of the epithelial barrier in this group led to approximately 50% reduction in the
percent increase in fetal glucose concentration as compared to the baseline data obtained
from the acellular model. When fetal endothelial cells were included to establish a coculture model, permeability decreased further due to the additional cell layer, and the
increase in fetal glucose was evaluated to be roughly 30% of that measured in the
trophoblast monoculture group. These results demonstrate the ability of the differentiated
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trophoblasts in our model to mediate glucose transport. It also indicates that the fetal
endothelium may have a previously underappreciated effect on the rate of glucose
transport by providing an additional barrier to facilitated diffusion.

Our analysis revealed that the percent rate of glucose transfer from the maternal to the
fetal compartments was 34.8%. Importantly, this value lies within the range of glucose
transfer rates measured in the perfused ex vivo human placenta (26.5-38.3%) (Figure
2.6F)
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, which is regarded as the gold standard for the study of human placental

transport11. Co-culture of trophoblasts and villous endothelial cells in Transwell inserts
yielded decreased transport at a reduced rate of 22.5% (Figure 2.6F), failing to fall within
the physiological range. These data serve to validate the physiological relevance of the
placenta-on-a-chip system and to demonstrate its advantage over conventional in vitro
techniques. The ability of our model to accurately approximate transport rates in the
human placenta is particularly compelling, as animal data poorly predict glucose transfer
across the human placental barrier due to interspecies differences in the molecular
underpinnings of transport function. For example, glucose transport in the murine and
rodent placenta is mediated predominantly by GLUT3, whereas GLUT1 is the primary
glucose transporter in the human placental barrier105.

Hence, our data illustrate the

feasibility of using the placenta-on-a-chip system as an alternative to existing animal
models to simulate physiological glucose transport across the intact human placental
barrier.
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2.4. Conclusion
In this chapter, we have presented a microphysiological system that reconstitutes the most
essential unit of the human placenta. The design of this placenta-on-a-chip microdevice
was inspired by the anatomy of the critical tissue-tissue interface that separates the
maternal and fetal circulations in pregnancy. This system has the potential to serve as a
powerful platform for in vitro investigation of the human placenta in that it allows for precise
spatiotemporal control of placental cells and their extracellular microenvironment to
simulate, directly visualize, and quantitatively analyze human-specific placental structure
and function. These capabilities provide new opportunities to create cell-based screening
assays for evaluating the placental transfer of pathogens, drugs, chemicals, and
environmental toxins. Our approach may also enable the development of specialized in
vitro models to mimic aberrant changes in the placental barrier under pathological
conditions of pregnancy. These types of microengineered systems will greatly improve our
ability to mechanistically examine and understand placental barrier dysfunction that has
been identified as an important feature of various pregnancy-related diseases.

The model in the form presented here, however, still leaves room for improvement to
realize its full potential. Although BeWo cells used in this study have proven effective for
recapitulating key aspects of the maternal-fetal interface, questions remain regarding the
validity of using these cancer-derived cells to represent the normal epithelium of the
placental barrier. To address this limitation, subsequent iterations of this system should
include culture of primary villous trophoblast cells for improved physiological relevance,
though implantation of this cell type on-chip is limited by obstacles outlined in Chapter 1
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of this dissertation. Subsequent work should also investigate transport of other essential
nutrients, such as amino acids and fatty acids, across the microengineered placental
barrier to further validate the predictive capability of our model. The effects of fluid flow
on microvilli formation and placental transport documented in this and previous studies
warrant more rigorous investigation of how placental structure and function are regulated
by hemodynamic forces and other microenvironmental cues. In addition, opportunities
remain in reconstituting the dynamic structural remodeling and functional adaptation of the
placental barrier during the progression of pregnancy. The results described in this chapter
clearly demonstrate the potential of utilizing microengineering technologies for the study
of the human placenta.

We believe that this work represents a first step towards

pioneering innovative research approaches that will improve our fundamental
understanding of human reproductive health and disease.
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CHAPTER 3. Placental hemodynamics influence trophoblast

phenotype in the human placental barrier

3.1 Introduction
As discussed, during human pregnancy, the placenta has an essential role in fetal growth
and development by regulating transfer of all substances between mother and baby. This
function includes the transport of nutrients from the maternal to fetal circulation, as well as
movement of waste products from the fetus back to the mother for excretion. At this critical
maternal-fetal placental interface, the syncytiotrophoblast is a unique cell type that makes
up the outer epithelial layer of the chorionic villi. It is in direct contact with maternal blood
and expresses a variety of specialized transport proteins, thus is vital for mediating
transplacental transfer106. At term, the syncytiotrophoblast has a surface area of
approximately 12 m2 to facilitate efficient transport to the fetus107. In addition to its transport
function, the syncytiotrophoblast plays an important endocrine role by producing
hormones that influence placental and fetal development in order to maintain a successful
pregnancy99,100. Hormones secreted by the syncytiotrophoblast exert autocrine and
paracrine effects and influence diverse gestational physiological processes, such as
immune tolerance, angiogenesis, and myometrial contractility. Dysfunctional hormone
production can result in adverse pregnancy outcomes.

The multinucleated syncytiotrophoblast is one of the few cell types that is capable of cell
fusion in the human body. It first develops after implantation and is maintained throughout
the course of pregnancy by the continuous fusion of cytotrophoblasts located in the
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chorionic villi108. Cell fusion is rare in the human body and as such is a tightly regulated
process that requires the concerted action of specialized proteins. First, the fusing
cytotrophoblast first exits the cell cycle. The precise molecular machinery is as yet
unknown, but an increase in cyclic adenosine monophosphate (cAMP) and activation of
protein kinase A (PKA) signaling occur109. This process can be studied in vitro with primary
villous trophoblasts, which spontaneously syncytialize, as well as BeWo cells, which can
be induced to fuse with cyclic AMP or forskolin supplementation88. These tools have
enabled progress in understanding some of the molecular mechanisms involved in
cytotrophoblast fusion. However, despite the importance of syncytialization in pregnancy
and the availability of in vitro research platforms, there is still a lack of knowledge regarding
the cues that regulate the process of cytotrophoblast fusion into the syncytiotrophoblast
and its spatiotemporal regulation.

Interestingly, the process of syncytialization has been found to be aberrant in certain
pathologies of pregnancy, such as preeclampsia and intrauterine growth restriction110. In
vitro culture of cytotrophoblasts from preeclamptic placentas demonstrated lower rates of
cell-cell fusion and reduced beta-human chorionic gonadotropin (b-hCG) 111. There is also
evidence that formation of the syncytiotrophoblast is defective in trisomy 21-affected
placentas112. Primary cultures of trophoblasts from trisomy 21 placentas exhibit reduced
fusion, though syncytialization can be increased through addition of hCG113. Since there
are still so many questions that remain about mechanistic regulation of trophoblast
syncytialization, it is unclear how its dysfunction relates to pathologies of pregnancy.
Further research is necessary to uncover whether it is pathogenic in the etiology of these
conditions or a byproduct of disease.
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Given the complex hemodynamic environment of the placental intervillous space,
increasing attention has been focused on the effects of fluid shear stress on placental cell
function. Recently, researchers used computational fluid dynamic simulations to
investigate the wall shear stress exerted by maternal blood flow on the chorionic villi of the
placenta114. Their study estimated that average wall shear stress levels are low (0.5-1.1
dyn/cm2), but highly variable throughout the intervillous space. Furthermore, these values
likely fluctuate throughout the course of gestation as changes maternal cardiac output,
uteroplacental flow, and placental development occur. Recent in vitro studies have
demonstrated that fluid shear stress does in fact impact aspects of trophoblast function,
like microvilli formation and growth factor secretion86,115,116.

Figure 3.1. The placental intervillous space is a dynamic fluid environment. Red
arrows denoting hemodynamics in the maternal intervillous compartment illustrate the
complex mechanical microenvironment within the placenta. The syncytiotrophoblast
of the chorionic villi, which is bathed in maternal blood, is in direct contact with these
mechanical forces. Until recently, very little was known about the fluid dynamics of the
placental intervillous space. However, recent work has determined levels of fluid
shear stress experienced at the surface of the chorionic villi.
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Our group has developed a microphysiological model of the human placental barrier, or
placenta-on-a-chip, that reconstitutes the maternal-fetal interface115,117. In this system, we
culture the two key cell types of the placental barrier, trophoblast and endothelial cells, in
a physiologically relevant spatial arrangement and have previously applied the platform to
study barrier formation and maternal-fetal transport. This system offers the unique ability
to control the dynamic microenvironment experienced by the cells cultured on-chip. Thus,
we have leveraged our system here to study the impact of fluid shear stress on trophoblast
cell phenotype. Organ-on-a-chip technology has been shown to be useful in elucidating
the relationship between fluid shear stress and cell function74,118. In the work presented in
this chapter, we examine the effects of placental hemodynamics on trophoblast
differentiation and function.

3.2 Materials and Methods
3.2.1. Cell Culture
BeWo trophoblast cells (b30 clone) were provided by Dr. Nicholas Illsley and maintained
in DMEM/F12K medium (GE Healthcare) containing 10% fetal bovine serum (FBS) and
1% penicillin-streptomycin.

3.2.2. Microdevice Fabrication
Placenta-on-a-chip microdevices were fabricated as previously described in Chapter 2115.
Briefly, following standard soft lithography techniques, poly(dimethylsiloxane) (PDMS)
base was mixed with curing agent at a 10:1 weight ratio, poured over a silicon master
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containing microchannel features, and cured at 65°C. The microchannel features were
500 µm wide and 80 µm high. Upper and lower microchannel slabs were bonded to a
polycarbonate membrane containing 1 µm pores (Whatman) using an adhesive PDMS
mortar layer. This layer was generated by mixing PDMS base and curing agent at a 10:3
weight ratio then spin-coating this mixture onto a Petri dish at 2500 rpm for 5 minutes.
Both microdevice slabs were placed on the PDMS mortar layer and then aligned with the
polycarbonate membrane sandwiched between.

3.2.3. Microfluidic Cell Culture
For BeWo trophoblast cell monoculture experiments, the microdevice was first sterilized
by UV irradiation. Next, the microchannels were filled with fibronectin solution (0.1 mg/mL
in PBS) and incubated overnight at 37°C. Following ECM coating, a BeWo cell suspension
of 4 million cells/mL was injected into the upper microchannel. The device was then
incubated for 1 hour in a cell culture incubator to enable cell adhesion to the ECM-coated
membrane. Once cell attachment was confirmed by microscopic inspection, the channel
was gently flushed with cell culture medium to remove unbound cells. The device was
then connected to a syringe pump for perfusion culture. Devices were maintained at a flow
rate of 30 µL/hr overnight to generate a fully confluent monolayer. Subsequently, the flow
rate was set based on the equation for shear stress within a rectangular microchannel,

𝜏=

#$%
&'(

, where µ is the viscosity of the cell culture media, Q is the volumetric syringe

pump flow rate, and w and h are the width and height of the microchannel, respectively.
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3.2.4. Static Transwell Culture
For static control experiments, Transwell inserts (Corning; 24-well, 0.4 µm pore size) were
first coated with fibronectin solution (0.1 mg/mL in PBS). BeWo cells were then introduced
into the apical chamber of the insert at a concentration of 178,000 cells/mL. The basal
chamber of the insert was also filled with trophoblast cell culture medium. Media was
changed every 48 hours for the duration of the experiments.

3.2.5. Immunofluorescence Analysis
After the completion of a study, the microdevice was removed from the syringe pump. The
samples were rinsed with PBS then filled with 4% paraformaldehyde for 15 minutes.
Following fixation, the cells were permeabilized with 0.25% Triton-X 100 for 10 minutes
and then incubated with 3% bovine serum albumin (BSA; in PBS) for 30 minutes. The
samples were then incubated with primary antibody diluted in 3% BSA (1:50) for 1 hour at
room temperature or at 4°C overnight. Subsequently, the samples were thoroughly
washed with PBS and incubated with secondary antibody diluted in 3% BSA (1:100) for
45 minutes at room temperature, and washed again with PBS. Nuclei were labeled using
DAPI. The polycarbonate membrane was then removed from the microdevice and
mounted onto a coverslip containing mounting medium (Dako). Images were acquired on
an inverted microscope (Zeiss Axio Observer) and a confocal laser-scanning microscope
(Leica TCS SP8). Images were processed using LAS-X software (Leica) and Volocity
(PerkinElmer).
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3.2.6. Reverse Transcription Quantitative Polymerase Chain Reaction
Analysis
For quantification of cellular mRNA, the device microchannels were perfused with Trizol
and perfusate was collected. Total RNA was extracted using an RNeasy Micro Kit
(Qiagen) according to the manufacturer’s protocol. Next, the samples were reverse
transcribed using an cDNA reverse transcription synthesis kit (Applied Biosystems).
Oligonucleotide primers were ordered from the University of Pennsylvania Cell Center for
human chorionic gonadotropin beta and GAPDH. RT-qPCR analysis was performed on
cells grown in static transwell and microfluidic cell culture conditions. Results are reported
as fold-change in expression compared to static control culture.

3.2.7. Statistical Analysis
Results are reported as mean ± standard deviation. Statistical significance was assessed
with a two-tailed Student’s t-test using Graphpad software. Each experiment was repeated
at least three times.

3.3 Results and Discussion
3.3.1. Establishment of microfluidic trophoblast cell culture
Building upon the work outlined in chapter 2, we utilized the placenta-on-a-chip system to
culture BeWo trophoblast cells under dynamic conditions and controlled the flow rate of
perfusion culture in order to achieve a desired level of fluid shear stress on the cell surface.
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As previously discussed, BeWo cells introduced into the upper microchannel firmly
attached to the fibronectin-coated polymeric membrane and proliferated to form a
confluent monolayer. Devices were perfused under low shear stress (0.10 dyn/cm2) or
high shear stress (1.00 dyn/cm2) conditions. Conventional Transwell culture techniques
were employed to enable comparison of dynamic culture to static conditions. In this setup,
BeWo trophoblast cells were seeded into the apical compartment of a Transwell insert
and established firm adhesion to the ECM-coated membrane. Similar to microfluidic
culture, cells cultured in Transwell proliferated to cover the entire membrane surface and
remained viable for the duration of experiments.

3.3.2. Morphological changes in response to fluid shear stress
Cytotrophoblasts are mononuclear and exhibit E-cadherin expression along the entirety
of their cell borders at points of contact with neighboring cells. During syncytialization,
morphological differentiation occurs and is associated with cell aggregation and a loss of
E-cadherin expression119. There is also a simultaneous change in cytoskeletal structure
during trophoblast fusion, as evidenced by F-actin staining120. Thus, we first examined
changes in E-cadherin expression in static and dynamic conditions over the course of 3
days of culture. BeWo cells cultured in static conditions for 72 hours retained a
cytotrophoblast-like morphology and exhibited a continuous network of intercellular Ecadherin junctional expression at areas of cell-cell contact, as illustrated in Figure 3.2A.
Similarly, BeWo cells maintained in the placenta-on-a-chip under dynamic conditions
demonstrate a similar E-cadherin expression at 24 hours of microfluidic culture (Figure
3.2B). However, BeWo cells subjected to 72 hours of fluid stress on-chip exhibit nuclear
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aggregation and a loss of E-cadherin expression areas of the cell monolayer (Figure
3.2C).

At 3 days of microfluidic culture, this pattern of expression does not occur

Figure 3.2. Changes in E-cadherin expression in response to fluid shear stress.
A. Following 72 hours of static culture, BeWo cells exhibited continuous E-cadherin
(red) expression throughout the cell monolayer. No significant aggregation of fusion
has occurred. Nuclei are counterstained with DAPI (blue). Scale bar = 30 µm. B. At
24 hours of microfluidic culture, BeWo exhibited a cytotrophoblast-like morphology
with widespread E-cadherin staining. Scale bar = 30 µm. C. Exposure to low shear
stress (left) and high shear stress (right) for 72 hours led to reduction in E-cadherin
expression in some areas of the BeWo monolayer. Scale bar = 30 µm.
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throughout the entire cell population, but is localized to discrete areas within the
monolayer.

The contrast in E-cadherin expression in cells exposed to dynamic flow compared to static
conditions indicates that fluid shear stress influences fusion-related morphological
changes in BeWo cells. Lecarpentier et al. recently determined that exposure to fluid shear
stress (1.0 dyn/cm2) resulted in increased cAMP production primary cytotrophoblasts116.
This response was detectable after application of shear stress for 45 minutes. Given that
fluid shear stress leads to increased intracellular cAMP and cAMP signaling results in
BeWo cell fusion, this is likely the mechanism that is leading to these changes in cells
cultured under dynamic flow on-chip. However, it will be important moving forward to
conduct further studies to confirm this mechanistic link. One approach would be to utilize
an inhibitor of the PKA signaling pathway, like H-89. Treatment of cells exposed to fluid
shear stress with this protein kinase inhibitor would help to elucidate the role of PKA in
mechanotransduction of these signals.

3.3.3. Biochemical differentiation and hormone production
An important aspect of trophoblast syncytialization involves biochemical differentiation
that enables synthesis of key placental proteins. In addition to the morphological changes
in junction expression, cell aggregation, and cytoskeletal reorganization that take place,
this functional differentiation results in syncytiotrophoblast production of hormones and
other factors essential to the progression and maintenance of pregnancy that are not
produced by cytotrophoblasts100. Syncytiotrophoblast secretion of these proteins, like
leptin, human chorionic gonadotropin, and placental alkaline phosphatase, impact a
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variety of aspects of placental function. In this study, we have examined the production of
b subunit of human chorionic gonadotropin (b-hCG) by fusing BeWo cells exposed to static
or dynamic conditions using immunofluorescence staining and qPCR analysis. This

Figure 3.3. b-hCG production in response to fluid shear stress. A. Static culture
yields no detectable synthesis of b-hCG (green). E-cadherin is stained in red and
nuclei are labeled with DAPI in blue. Scale bar = 30 µm. B. Low shear stress on-chip
leads to low levels of b-hCG in some cells. Scale bar = 30 µm. C. Exposure to high
shear stress has increasing levels of b-hCG compared to the low shear condition.
Areas of protein biosynthesis coincide with dissolution of E-cadherin junctions. Scale
bar = 30 µm. D. As a positive control, forskolin treatment in static culture induces bhCG production in a small number of cells throughout the BeWo monolayer. Scale bar
= 30 µm. E. Quantitative real-time PCR shows a shear stress level-dependent
increase in b-hCG mRNA expression. All expression was normalized to GAPDH and
fold change was calculated from static culture control. (**, p<0.01).
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protein is used to detect pregnancy in humans and is also often used a biomarker to
evaluate trophoblast differentiation in in vitro culture.

At 72 hours of culture, b-hCG production is absent in static conditions based on
immunofluorescence analysis (Figure 3.3A). As previously discussed, BeWo cells in static
culture retained their cytotrophoblast-like phenotype as small mononuclear cells with a
continuous junctional network of E-cadherin expression. Staining for b-hCG produced no
detectable signal. Application of low shear stress resulted in low levels of b-hCG
biosynthesis in some cells of the BeWo monolayer, as shown in Figure 3.3B. However,
the fluorescence intensity of staining for b-hCG is low in this condition. Exposure to high
shear stress yielded increased staining of b-hCG (Figure 3.3C). A greater number of cells
in the BeWo population demonstrated enhanced fluorescence, indicating an increase in
biochemical differentiation. These positively staining cells correspond with areas where
there is nuclear aggregation and a loss of E-cadherin expression. Finally, these results
were compared to a positive control where BeWo cells in static conditions were exposed
to 50 µM forskolin. Treatment with forskolin leads to the highest intensity b-hCG
expression, though it is still only present in a small number of cells (Figure 3.3D). After
observation of these changes using immunofluorescence staining, we then utilized
quantitative PCR to analyze differences in gene expression. As shown in Figure 3.2E, at
day 3 of culture, there is in an increase in b-hCG mRNA expression in both the low and
high shear stress conditions compared to static culture. This is shear stress leveldependent, as the fold-change in expression in the high shear condition is nearly double
that of the low shear group.
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3.3.4. Combinatorial effects of forskolin and shear stress
Cyclic AMP and forskolin can be used to induce cell fusion in BeWo b30 cell culture88.
These factors affect cAMP metabolism, which in turn upregulates the PKA pathway and
triggers action of fusogenic activity in the trophoblast cell membrane leading to
syncytialization97. The discovery of the effect of cAMP signaling in trophoblast biology was
based in part on the knowledge of the importance of cAMP in myoblast fusion. It has since
become commonplace in tissue culture of BeWo trophoblast cells to utilize cAMP or

Figure 3.4. Forskolin-induced fusion was increased by exposure to shear
stress. A. In static culture, forskolin treatment leads to morphological changes
and biochemical differentiation with b-hCG production (green). However, many
cells in the BeWo population retain a cytotrophoblast-like morphology, as
illustrated by E-cadherin expression (red). Nuclei are counterstained with DAPI
(blue). Scale bar = 30 µm. B. A combination of shear stress and forskolin
treatments yields b-hCG synthesis and a more pronounced loss in E-cadherin
expression in BeWo cells. Scale bar = 30 µm. C. At day 3, qPCR analysis shows
a large increase in b-hCG mRNA expression with forskolin treatment. This
expression is further increased with combined forskolin and shear stress
exposure. All mRNA expression was normalized to GAPDH and fold expression
was calculated from a static control. (**, p<0.01; ****, p<0.0001).
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forskolin to model the syncytiotrophoblast in vitro. However, many questions still remain
regarding the spatiotemporal regulation of cAMP/PKA signaling in fusion events as well
as the role of other factors in mediating this complex biological process.

In our system, we examined the effects of a combination of forskolin and shear stress onchip by evaluating morphological changes and b-hCG production in BeWo cells. Figure
3.4A depicts E-cadherin and b-hCG expression in BeWo cells cultured in static conditions.
The addition of forskolin in static culture led to breakdown of junction expression through
the BeWo monolayer and production of b-hCG in a small number of cells. There is overlap
in the areas where these alterations are observed, indicating both morphological and
biochemical differentiation has taken place in the affected cells. These changes are more
pronounced in the cells exposed to a combination of forskolin and high shear stress in the
placenta-on-a-chip (Figure 3.4B). Very few cells exhibited E-cadherin expression at their
borders, which represents indicates fusion in the BeWo population.

Using quantitative PCR, we evaluated mRNA expression of b-hCG in forskolin-treated
static and dynamic conditions. This analysis demonstrated a 78-fold increase in b-hCG
expression in forskolin-treated static Transwell culture compared to untreated static
culture (Figure 3.4C). This upregulation was more significant than the 7-fold increase in bhCG expression in devices cultured under high shear stress without addition of any
exogenous factors. Interestingly, however, the forskolin-treated high shear stress group
exhibited the greatest increase in b-hCG mRNA with a 118-fold change compared to static
control. This indicates there is a synergistic effect in the combined application of forskolin
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and shear stress on trophoblast cells. Based on these data, the exposure to dynamic flow
amplifies the response of BeWo cells to forskolin.

3.4 Conclusion
The work presented in this chapter indicates that the placental trophoblast is a
mechanosensory cell type that is capable of detecting and adapting to the mechanical
microenvironment. This builds upon the results of recent studies that have demonstrated
a link between fluid shear stress and trophoblast phenotype as well as cellular protein
biosynthesis86,116,121. The use of the placenta-on-a-chip system in this work enabled
precise control over the dynamic microenvironment in order to simulate the conditions of
placental hemodynamics. This platform allowed for tunable control of fluid shear stress
levels and subsequent direct observation and high resolution analysis of trophoblasts
cultured on-chip. However, the current model could be improved through use of primary
villous trophoblasts in the place of BeWo cells. Although BeWo cells are widely used as a
model of the human cytotrophoblast, there are limitations in the use of a cancer cell line
to represent the syncytiotrophoblast, as previously discussed in prior chapters of this
dissertation. Thus, repeating these studies with culture of primary villous trophoblasts onchip would improve the physiological relevancy of the work presented in this chapter.
Furthermore, these studies were carried out in trophoblast monoculture conditions in the
placenta-on-a-chip. Future work should incorporate placental villous endothelial cell coculture on-chip to ascertain whether the cells located in the fetal capillaries also exert
paracrine effects on trophoblast phenotype in response to fluid shear stress.
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The association between fluid shear stress and trophoblast function may also play a role
in pathological pregnancies. The abnormal syncytium formation that occurs in
preeclampsia and intrauterine growth restriction could potentially relate to altered
placental hemodynamics in the intervillous space. For example, defective cytotrophoblast
fusion and a reduction in placental growth factor (PlGF) levels are both observed in
preeclamptic pregnancies122,123. Cell fusion and PlGF secretion have both been shown to
be influenced by fluid shear stress116, thus may relate the etiology of these conditions.
Previous research has focused on the role of growth factors and hormones on
development of preeclampsia. However, future research should incorporate further
examination on the role of the mechanical microenvironment of the placenta on its
development and function and the placenta-on-a-chip is a platform well-suited to enabling
such research.
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CHAPTER 4. Leveraging the placenta-on-a-chip to study
maternal-fetal drug transfer

This chapter is amended from the paper, “A microengineered in vitro model of transportermediated drug efflux in the human placental barrier” in Advanced Healthcare Materials
(Blundell et al. 2017).

Abstract
The current lack of knowledge about the effect of maternally administered drugs on the
developing fetus is a major public health concern worldwide. The first critical step towards
predicting the safety of medications in pregnancy is to screen drug compounds for their
ability to cross the placenta. However, this type of preclinical study has been hampered
by the limited capacity of existing in vitro and ex vivo models to mimic physiological drug
transport across the maternal-fetal interface in the human placenta. Here we demonstrate
the proof-of-principle for utilizing a microengineered model of the human placental barrier
to simulate and investigate drug transfer from the maternal to the fetal circulation. Using
the gestational diabetes drug glyburide as a model compound, we show that our
microphysiological system is capable of reconstituting efflux transporter-mediated active
transport function of the human placental barrier to limit fetal exposure to maternally
administered drugs. Our data provide evidence that the placenta-on-a-chip may serve as
a new screening platform to enable more accurate prediction of drug transport in the
human placenta.
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4.1. Introduction
Fetal exposure to medications is a critical issue in pregnancy that can lead to serious
gestational complications and long-term health consequences. A recent survey of clinical
data from 1976 to 2008 reported that approximately 90% of women in the United States
take at least one medication during pregnancy124. Moreover, retrospective studies have
reported significantly increasing use of over-the-counter and prescription drugs by
pregnant women. In the United States, for instance, the fraction of women taking four or
more medications during pregnancy has more than doubled over the past three decades
and continues to rise125. Despite this alarming trend, the risks posed by maternally
administered drugs to the developing fetus remain a largely unanswered question to both
clinicians and expecting mothers.

One of the major contributors to this problem is our limited ability to model and predict the
physiological transport function of the human placenta. The placenta is responsible for
regulating the transfer of all materials between the mother and the fetus during pregnancy,
and therefore plays an essential role in fetal exposure to drugs1. To assess the safety of
medications in pregnancy appropriately, it is imperative to first understand whether and
how drug molecules cross the placental barrier from the maternal to the fetal circulation.
While animal models of pregnancy provide useful surrogates for these types of studies,
considerable interspecies differences in placental structure and function have rendered
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Figure 4.1. The human placenta and placenta-on-a-chip. A. Three-dimensional
cross section of the human placenta illustrates cotyledons, which contain chorionic
villi bathed in the maternal blood in the intervillous space. B. A zoomed-in view
highlights the fetal capillaries that are located within the chorionic villi. C. The placental
barrier that separates the maternal intervillous space from the fetal capillary lumen
consists of two cell types: the syncytiotrophoblast and fetal endothelial cells separated
by a thin interstitial tissue layer. D-E. The placenta-on-a-chip is a microengineered
model designed to recapitulate the multi-layered three-dimensional architecture of the
placental barrier. Within the device, trophoblast and endothelial cells are co-cultured
on the opposite sides of a thin porous polymeric membrane. During culture, the
viability of the cells is maintained by continuous low of culture medium on both sides
of the membrane.
the use of these models controversial16,126. The inadequacy of preclinical animal testing is
best highlighted by the tragedy of thalidomide in the 1960s that caused serious birth
defects and fetal deaths due to the failure of animal models to predict human fetal
toxicity127. Despite significant progress in animal experimentation for reproductive
toxicology, the predictive value of animal data continues to be questionable. As a result,
alternative strategies are urgently needed for the preclinical assessment and accurate
prediction of drug transfer across the human placenta and subsequent fetal exposure.
75

To address this critical unmet need, in this chapter we demonstrate the proof-of-principle
for using a human cell-based microphysiological model of the placenta for simulation and
quantitative analysis of placental drug transport. This study builds upon the placenta-ona-chip work outlined in this dissertation to mimic the salient structure and function of the
human placental barrier (Figure 4.1A-C) 115. In this microdevice, human trophoblast cells
and villous endothelial cells are cultured in apposition on a semipermeable membrane
under flow conditions (Figure 4.1D-E). This configuration makes it possible to reconstitute
the multilayered architecture and hemodynamic environment of the placental barrier,
providing compelling advantages over existing in vitro models based on static culture of
trophoblast monolayers in Transwell inserts8. In comparison to traditional ex vivo
approaches using extracorporeal perfusion of cannulated whole human placenta67,71, our
model is more attractive for mechanistic investigation due to its ability to precisely control
and manipulate various key parameters of placental drug transport.

In the present study, we leverage these unique capabilities to recapitulate physiological
function of the human placental barrier to regulate maternal-to-fetal transfer of drugs that
are commonly used during pregnancy. A specific focus of our investigation is on active
drug transport mediated by the breast cancer resistance protein (BCRP), which is one of
the major ATP-binding cassette (ABC) efflux transporters abundantly expressed in the
apical membrane of trophoblast cells in the placenta128. Studies have shown that BCRP
plays a central role in limiting fetal drug exposure by pumping various types of maternally
administered drug compounds from the fetal compartment back into the maternal
circulation129. We demonstrate the ability of our placenta-on-a-chip model to mimic this
critical BCRP-mediated transport function using a model drug, glyburide – a BCRP
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substrate and an oral medication used to treat diabetes in pregnancy. Our data show that
the in vitro human placental barrier engineered in our device reconstitutes physiological
expression of BCRP in trophoblast cells and emulates the protective role of its in vivo
counterpart by effectively preventing transfer of glyburide from the maternal to the fetal
compartment.

The work described herein represents an important step towards the development of
human-relevant predictive in vitro models for preclinical evaluation of drug safety in
pregnancy. The placenta-on-a-chip system holds great potential as a promising alternative
to traditional models in reproductive toxicology and offers a novel platform to screen drug
transport in the human placenta in a rapid and cost-effective manner. We believe that our
technology provides a technical basis for more systematic investigations in the future and
may eventually allow clinicians to make informed decisions and recommendations to
pregnant mothers.

4.2. Experimental Section
4.2.1. Cell Culture
BeWo b30 cells were maintained in DMEM/F-12K medium (GE Healthcare) containing
10% fetal bovine serum (FBS), 1% L-glutamine and 1% penicillin/streptomycin (Gibco).
Human placental villous endothelial cells (HPVECs) isolated from term placentas following
a previously published protocol89 and cultured in EGM-2 media containing 2% FBS
(Lonza).
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4.2.2. Microfluidic Device Fabrication
Placenta-on-a-chip devices were fabricated following standard soft lithography protocols
outlined in chapters 2 and 3. Poly(dimethylsiloxane) (PDMS) (Sylgard, Dow Corning) base
was mixed thoroughly with curing agent at a ratio of 10:1. This mixture was then poured
over a photolithographically prepared silicon master containing microchannel features
fabricated in a negative photoresist, SU-8 (MicroChem). The dimensions of the
microchannels were 1 mm (width) x 1.5 cm (length) x 135 µm (height). The PDMS was
degassed and then incubated at 65C to induce polymerization. Once fully cured, the
channel slab was peeled off of the master, and through-holes were made through the slab
using a 1 mm biopsy punch to generate inlet and outlet access ports. For device assembly,
PDMS stamping was used to bond the upper and lower slabs to a semipermeable
polycarbonate membrane (1 µm pores, GE Healthcare) as previously described90. In this
technique, the upper channel slab was stamped onto a thin (~10 µm) layer of uncured
PDMS and then bonded to the lower channel slab. During this step, the intervening
membrane was sandwiched between the two channel layers.

4.2.3. Microfluidic Cell Culture
Following fabrication, the PDMS microchannels were filled with 70% ethanol and
incubated for 1 minute. The ethanol solution was then removed from the channels by
vacuum aspiration applied to the access ports of the upper and lower microchannels. This
step was repeated until complete removal of the solution was achieved. The device was
then placed under ultraviolet light for a 20-minute sterilization cycle. Next, to prepare the
polycarbonate membrane for cell seeding, the microchannels were filled with human
fibronectin solution (0.1 mg/ml in PBS) and incubated at 37C for a minimum of 4 hours.
78

This solution was rinsed with PBS prior to the introduction of cells. Trypsinized HPVECs
at a concentration of 4 x 106 cells/ml were first introduced into the lower microchannel.
The device was inverted and incubated for 1 hour in a cell culture incubator to enable
attachment of the cells to the lower surface of the membrane. Following endothelial cell
adhesion, BeWo cells were subcultured and injected into the upper microchannel at a
concentration of 4 x 106 cells/ml. The microdevice was again incubated at 37C for at least
1 hour for BeWo cell attachment. Once complete cell attachment was confirmed, the
device was connected to a syringe pump (Chemyx) for continuous perfusion at a flow rate
of 100 µl/h. To induce syncytialization, the BeWo cells in the upper microchannel was
perfused with DMEM/F12-K medium (GE Healthcare) containing 50 µM forskolin (Sigma).
The lower microchannel containing HPVECs was perfused with EGM-2 medium (Lonza).

4.2.4. Barrier Characterization
Cells cultured in our microfluidic devices were fixed in 4% paraformaldehyde (PFA) for 15
minutes and permeabilized in 0.25% Triton X-100 for 10 minutes, with thorough rinse
steps in between. Next, the channels were filled with 2% bovine serum albumin (BSA) for
1 hour at room temperature. For imaging of intercellular junctions, BeWo cells were
incubated with anti-E-cadherin (Life Technologies) and HPVECs were incubated with antiVE-cadherin (Cell Signaling Technologies) for 1 hour. Following a PBS rinse, secondary
antibodies diluted in 2% BSA (Life Technologies) were introduced into the microdevice
and incubated for 45 minutes. For visualization of trophoblast microvilli and the actin
cytoskeleton, cells were exposed to Alexa Fluor 488 conjugated phalloidin (Life
Technologies) for 30 minutes. Finally, DAPI was utilized to stain cell nuclei.
Immunofluorescent images were acquired using a confocal laser-scanning microscope
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(Leica TCS SP8) and inverted microscope (Zeiss Axio Observer). Volocity (PerkinElmer)
was utilized for image processing.

4.2.5. Analysis of Cell Fusion
Fusion of BeWo cells following forskolin treatment was analyzed using MATLAB and
CellProfiler. These values were calculated from 3-5 images at each time point. A MATLAB
script was utilized to segment nuclei based on thresholding and subsequently quantify
nuclear characteristics, including area, in pixels. Changes in nuclear area indicated
aggregation and fusion of BeWo cell nuclei. Junction segmentation was performed with
CellProfiler by applying maximum correlation thresholding to the E-cadherin channel
followed by intensity-based object identification and de-clumping130,131. By segmenting
based on E-cadherin expression, the area of individual cells could be measured. The
quantification of changes in cell area enabled analysis of progressive forskolin-induced
cell fusion in the BeWo cell population.

4.2.6. TEER measurements
A digital voltage-ohm multimeter (Fluke Corporation) was used to measure TEER under
co-culture conditions. The electrodes were placed into the outlet tubing of each channel
for analysis. Baseline measurements were made in acellular devices and subtracted from
the results in the co-culture devices.
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4.2.7. Permeability assay
Fluorescein isothiocyanate-inulin (FITC-inulin, Sigma) was diluted to a concentration of 1
mg/mL in serum-free DMEM/F12K medium. This solution was perfused through the upper
microchannel, and perfusates from both microchannels were assessed following 3 hours
using a microplate reader (Tecan).

4.2.8. Measurement of Fluorescein-Heparin Transport
Green-fluorescent fluorescein heparin conjugate (Thermo Fisher) was diluted to a
concentration of 0.05 mg/mL in DMEM/F12K medium. The fluorescent heparin solution
was perfused through the upper microchannel, and outflow was collected from both
channels following a 5-hour perfusion. The duration of drug perfusion was chosen to
ensure sufficient sample volumes for transport analysis. Fluorescence levels of the
maternal and fetal channel perfusates were quantified using a microplate reader (Tecan).
These steps were carried out in both co-culture and bare membrane (acellular) conditions
on-chip.

4.2.9. Analysis of Glyburide Transport
For both monoculture and co-culture glyburide transport studies, BODIPY-conjugated
glyburide was diluted into serum-free DMEM/F-12K medium and used at a final
concentration of 1 µM. The microdevice was connected to a syringe pump for infusion,
with drug-containing medium perfused through the upper microchannel and serum-free
EGM-2 medium in the lower microchannel. Following a 30-minute equilibration phase,
outflow was serially collected in 30 minute intervals, and fluorescence was quantified using
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a microplate reader (Tecan). Where appropriate, a standard curve was generated to
enable calculation of drug concentrations from mean fluorescence intensity of each
sample. Following the time course study, the microdevice was imaged using an inverted
microscope (Zeiss Axio Observer) to assess intracellular drug accumulation. For inhibitor
studies, Ko143 (150 nM in DMSO, Sigma) was added to the drug-containing medium
perfused continuously in the upper microchannel. Each transport study was repeated in 6
devices.

4.2.10. Statistical analysis
Results were presented as mean ± S.E.M. Statistical analysis was carried out using a twotailed Student’s t-test.

4.3. Results and Discussion
4.3.1. Production of the microengineered human placental barrier
As illustrated in Figure 4.1C, the in vivo placental barrier is a multilayered structure that
consists of trophoblast and fetal endothelial cells, which are separated by basement
membrane. As pregnancy progresses, this villous membrane becomes gradually thinner
and reaches an average thickness of approximately 4.53 µm at term, as determined by
measurements made in placentas following cesarean delivery132. Formation of appropriate
intercellular junctions in these tissue layers is crucial for physiological barrier function of
the placenta to mediate transfer of substances in the maternal blood from the intervillous
space to the fetal capillaries. Perfusion co-culture of human trophoblasts and human
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placental villous endothelial cells (HPVECs) in our compartmentalized microfluidic device
provided a means to recapitulate this important feature of the placental barrier. The cells
plated on either side of a fibronectin-coated semipermeable membrane were observed to
proliferate continuously and form confluent monolayers within 24 hours of cell seeding. By
72 hours of culture, the HPVECs had grown out of the membrane surface to cover all four
channel walls in the lower microchannel. Typically, the cells were cultured for 3 days under
continuous perfusion of medium to establish a bi-layer tissue structure reminiscent of the
trophoblast-endothelial

interface

of

the

placental

barrier

in

vivo.

Importantly,

immunofluorescence imaging illustrated the formation of continuous intercellular junctional
complexes in both cell types. The trophoblast cell and HPVEC populations showed robust
expression of E-cadherin and vascular endothelial (VE)-cadherin, respectively (Figure
4.2A,B). Our analysis revealed no visible intercellular gaps, suggesting the formation of
continuous monolayers on either side of the membrane. The structural integrity of the
microengineered barrier was confirmed by our analysis of electrical resistance across the
trophoblast-endothelial interface. This study showed that the transepithelial-endothelial
electrical resistance (TEER) measured in the co-culture system increased rapidly over
time and reached approximately 5020 Ω·cm2 when the cells were allowed sufficient time
(typically over 2 days) to form fully confluent monolayers.

To further assess barrier function of our model, we also conducted a permeability assay
to measure the passage of FITC-conjugated inulin across the microengineered placental
barrier. Control experiments using acellular devices revealed significant transfer of FITCinulin from the maternal to the fetal compartments, as evidenced by more than 25%
increase in the fluorescence intensity of fetal outflow over a period of 3 hours (Figure
4.2C). In contrast, the co-culture model showed no detectable florescence in the fetal
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chamber, illustrating negligible transport of FITC-heparin across the trophoblastendothelial barrier. Combined with the intercellular junction staining data and TEER
measurements, these results clearly demonstrate the formation of a microengineered
tissue-tissue interface with structural integrity and appropriate barrier function.

Another key feature of the human placental barrier that influences drug transfer is the
microvilli on the apical surface of the syncytiotrophoblast. These cellular protrusions serve
to increase the overall placental surface area for maternal-to-fetal transport, which
increases significantly over the course of gestation133. Our microengineered model
enabled reproduction of this physiological phenotype as well. In microscopic visualization
using actin staining, we observed that fine hair-like projections covered the entire cell
surface of the vast majority of trophoblast cells cultured in our microdevice (Figure 4.2D).
Although intercellular variability was observed in their size and density, these microvilli
were generated on the apical side of the cells facing the maternal compartment, matching
the polarity of syncytiotrophoblast microvilli in vivo (Figure 4.2E). In Chapter 2 of this
dissertation, we have shown that the extent of microvilli formation is reduced considerably
when trophoblasts are cultured on a similar semipermeable membrane support in a static
Transwell insert115. In conjunction with this previous finding, our results indicate that
dynamic culture conditions due to continuous perfusion in our model is beneficial not only
for maintaining cell viability but also for inducing cultured trophoblasts to recapitulate their
native morphological characteristics. Considering that a variety of active membrane
transporters implicated in the transfer of drugs and xenobiotics are expressed on the
microvillous surface of trophoblast cells2, the formation of abundant microvilli
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demonstrated here represents a critical requirement for reconstituting physiological drug
transport across the placental barrier.

Figure 4.2. Microengineered in vitro placental barrier. A. BeWo cells cultured on
the upper side of the porous membrane form a continuous epithelial barrier. Red
shows E-cadherin staining. Scale bar: 55 μm. B. Human placental villous endothelial
cells (HPVECs) are grown to confluence on the lower side of the membrane.
Widespread expression of VE-cadherin (green) illustrates the structural integrity of the
endothelial tissue. Scale bar: 36 μm. C. The microengineered placental barrier
effectively prevents the transfer of FITC-inulin from the maternal microchannel to the
fetal compartment, demonstrating appropriate barrier function. D. Dense microvilli
cover the surface of the BeWo cell population, as illustrated by F-actin staining
(green). Scale bar: 20 μm. E. A cross-sectional view of actin-stained BeWo cells
reveals the apical microvilli projections protruding from the cell body. Scale bar: 6 μm.
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4.3.2. Induction and characterization of trophoblast syncytialization
The placental barrier undergoes continuous and significant alterations in its structure
during pregnancy134. This structural evolution allows for more efficient exchange of vital
substances between the mother and the fetus while enhancing barrier function of the
placenta to further restrict the penetration of foreign materials into the fetal circulation.
Central to this physiological development is progressive intercellular fusion of
cytotrophoblasts on the maternal surface of the chorionic villi that eventually leads to the
formation of a multinucleated barrier termed the syncytiotrophoblast. Given the integral
role of trophoblast cells in placental drug transport, the process of syncytialization is an
important feature that needs to be recapitulated in in vitro platforms for screening the
safety of drugs for use in pregnancy.

To induce trophoblast syncytialization in our model, we used forskolin to increase
intracellular levels of cyclic adenosine monophosphate (cAMP) in the BeWo b30 clone88.
When these cells were perfused with forskolin-containing medium, progressive cell fusion
occurred over the duration of treatment (Figure 4.3A). In the first 24 hours, most of the
cells retained a cytotrophoblast-like morphology but prolonged treatment resulted in
noticeable changes characterized by cytoplasmic fusion and nuclear aggregation in a
significant fraction of the cells. Our quantitative morphometric analysis showed more than
a 38% increase in average cell area from 24 to 72 hours, indicating forskolin-induced cell
fusion (Figure 4.2B). Aggregation of cell nuclei was also evident from a significant increase
in the nuclear area that occurred during the same period (p < 0.0001) (Figure 4.2C).
Although syncytialization of the entire monolayer was not achievable even in further
extended treatment, this method serves to significantly improve the physiological
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relevance of our model and also provides the opportunity to more realistically simulate
drug transfer across the native placental barrier.

Figure 4.3. Microengineered in vitro placental barrier. A. Extended forskolin
treatment induces a significant loss of intercellular junctions (red) and syncytializationlike cell fusion in BeWo cells over the course of 72 hours. Scale bars: 55 μm. Blue
shows nuclear staining. B. During image analysis of E-cadherin staining, individual
cells are pseudo-colored to delineate cell-cell junctions and to quantify cell area during
forskolin treatment. The average area of BeWo cells increases over 72 hours,
illustrating progressive cell fusion in the trophoblast population. * and ** indicate p <
0.05 and p < 0.01, respectively. C. Another method for image analysis of cell fusion is
to segment DAPI-stained nuclei of BeWo cells and then measure the area of the
segmented nuclei. The average size of cell nuclei increases during forskolin treatment.
*** and **** indicate p < 0.001 and p < 0.0001, respectively.

87

4.3.3. Heparin transport across the placental barrier
Prior to investigating active drug transport using the placenta-on-a-chip model, we first
examined whether our microengineered placental tissue had the capacity to form an
effective barrier to soluble molecules and to properly mimic restrictive barrier function of
the maternal-fetal interface in vivo. Specifically, we used fluorescently labeled heparin as
a tracer to analyze molecular transport from the maternal compartment to the fetal
microchannel. Heparin is an anticoagulant medication used in the treatment of deep vein
thrombosis and pulmonary embolism during pregnancy135. It has been established that
heparin does not cross the placental barrier due to its large molecular size (3000-15000
kDa), offering a safe alternative to other anticoagulants, such as warfarin, which can be
transferred to the fetal circulation and exert deleterious effects on the developing
fetus136,137.

In our study, we exploited this non-permeable property of heparin to assess barrier
integrity of the microengineered placental interface. Our analysis was carried out by
administering fluorescently conjugated heparin into the maternal compartment and
subsequently measuring the fluorescence intensity of outflow collected from both
microchannels to quantify heparin transport. As a control condition, we first tested acellular
devices that consisted of bare semipermeable membrane supports without trophoblast
cells and HPVECs. In this case, the fetal perfusate sampled over the course of 5 hours
showed high levels of fluorescence, corresponding to 11.3% of the initial heparin
concentration in the maternal compartment (Figure 4.4A). When the same assay was
conducted in the co-culture system, however, fluorescence intensity of collected samples
was reduced dramatically and was negligible as compared to that measured in the
88

acellular model (p < 0.01) (Figure 4.4A). Under this condition, the final fetal concentration
of fluorescein-heparin was estimated to be approximately 0.2% of the initial maternal
concentration. These data indicate that our microengineered tissue can effectively prevent
the passage of heparin into the fetal compartment, confirming previous findings about
heparin transport in the human placenta. Our results also suggest the ability of our model
to recapitulate the barrier integrity that prevents the passage of heparin across the
placental barrier in vivo.

4.3.4. Active drug transport mediated by the microengineered placental
barrier
In the next phase of the study, we explored the possibility of simulating active drug
transport function of the placental barrier in our microfluidic device. For this investigation,
we used glyburide as a representative example of a medication commonly prescribed and
administered to pregnant women. Glyburide is a second-generation sulfonylurea widely
used in the treatment of gestational diabetes, which is a condition that affects up to 10%
of pregnancies in the United States and is becoming increasingly prevalent worldwide46,138.
With the rapidly growing use of diabetes drugs in pregnancy, extensive research has been
undertaken in the past decades to evaluate the transfer of glyburide in the human
placenta. Several ex vivo perfusion and clinical studies have reported that maternally
administered glyburide is nearly undetectable or found in very low concentrations in the
fetal circulation even at concentrations far exceeding therapeutic doses139-141. Increasing
evidence now suggests that the limited placental transfer of glyburide is achieved through
the function of ABC efflux transporters expressed by trophoblasts that actively pump the
drug against a concentration gradient into the maternal circulation142,143. Based on this
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knowledge, we asked whether our placenta-on-a-chip model was capable of mimicking
active transport of glyburide mediated by BCRP, which is one of the most important and
abundant efflux transporters in the human placenta144.

Figure 4.4. Drug transport in the placenta-on-a-chip. A. The kinetics of drug
transport across the microengineered placental barrier is examined by perfusing the
maternal microchannel with fluorescently labeled substrate and measuring
fluorescence in the perfusates. B. Transfer of fluorescein-heparin from the maternal
compartment to the fetal chamber is evaluated by measuring mean fluorescence
intensity (MFI) of perfusate collected from the fetal microchannel. Acellular devices
allow a significant fraction of maternally administered heparin to move across the
membrane into the fetal compartment, whereas the barrier covered with trophoblast
cells and endothelial cells (co-culture) effectively blocks heparin transport. ** shows
p < 0.01. C. BeWo cells exhibit widespread expression of BCRP (red). Blue shows
cell nuclei. Scale bar: 36 μm. D. BCRP is localized to the maternal-facing microvillous
membrane of BeWo cells. E. Quantification of fluorescence intensity of the apical and
basolateral membranes indicates localization of BCRP to the apical cell membrane.
**** shows p < 0.0001. Scale bar: 36 μm.
90

First, we measured and characterized the expression of BCRP in the microengineered
placental barrier. When syncytialized trophoblast cells were immunostained and imaged
using confocal microscopy, they showed robust BCRP expression throughout the
monolayer (Figure 4.4C). Importantly, transporter expression was localized to the apical
microvillous surface of the cells (Figure 4.4D-E), closely matching the spatial distribution
of BCRP reported in vivo128.

Figure 4.5. Drug transport in the placenta-on-a-chip. A. In the co-culture model,
a continuous increase in the fluorescence of maternal perfusate indicates transportermediated efflux of glyburide back into the maternal circulation. The fluorescence of
perfusate from the fetal compartment remains low and constant, showing limited
transfer. B. Under endothelial cell monoculture conditions, maternal glyburide
concentration is decreased. **** indicates p < 0.0001. C. Microscopic analysis
illustrates accumulation of glyburide in the BeWo cell monolayer, but no visible
fluorescence in the HPVEC population. **** indicates p < 0.0001.
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To investigate glyburide transport, we then introduced culture medium containing 1 µM
BODIPY-conjugated glyburide into the upper maternal channel and monitored the
fluorescence of perfusate retrieved from the fetal compartment (Figure 4.5A). Both sides
of the barrier were perfused continuously throughout the duration of the experiments to
simulate the hemodynamic environment of the placenta in vivo. In the absence of cells
cultured on the membrane support, the concentration of glyburide in the maternal
perfusate remained virtually constant without significant fluctuations over time (Figure
4.5A). In comparison to this acellular model, the BeWo-HPVEC barrier showed an entirely
different temporal profile of the maternal drug concentration. The concentration of
glyburide at early time points were measured to be considerably lower (e.g., 5-fold
reduction at 30 min) (Figure 4.5A), indicating a significant loss of drug from the maternal
circulation. We suspect that this is presumably due to drug uptake by the trophoblast cells
facing the maternal side, as evidenced by strong green fluorescence detected in this cell
population after 3-hour perfusion with BODIPY-labeled glyburide (Figure 4.5C). It should
be noted that PDMS can absorb glyburide (Figure 4.6) and thus may serve as another
source of drug loss from the maternal flow145. Considering that the acellular device made
out of the same material still yielded high maternal glyburide concentrations, however, the
contribution of PDMS drug absorption may not be as significant as cellular uptake (Figure
4.6).

Interestingly, the initially low concentration of glyburide began to rise and continued to
increase over time, eventually reaching the levels that were almost 4 times higher by the
end of 3-hour drug perfusion (Figure 4.4A). We speculate that this significant increase is
attributed to BCRP-mediated active transport of BODIPY-glyburide absorbed by the
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placental barrier back into the maternal circulation. Another important observation was
that the fetal concentration of glyburide remained constant and considerably lower than
the maternal concentration throughout perfusion. Additionally, microscopic imaging of
HPVECs after drug treatment yielded no detectable intracellular fluorescence (Figure
4.5C). These results were compared to glyburide transport in endothelial monoculture
conditions, where only HPVECs were present on the lower surface of the polycarbonate
membrane. Under these conditions, the progressive increase in maternal drug
concentration seen in the co-cultured placental barrier was no longer observed (Figure

Figure 4.6. Absorption of glyburide into PDMS. To assess the degree of PDMS
absorption of glyburide in the placenta-on-a-chip, a single microchannel (1 mm W x
1.5 cm L x 135 um H) was perfused with 1 μM BODIPY glyburide. The microdevice
was imaged in cross-section at 30, 60, and 120 minutes to visualize absorption of
fluorescent substrate into the channel walls. A-B. The baseline PDMS at 0 minutes
shows no fluorescence. Starting at 30 minutes, green fluorescence is visible along
the upper surface of the channel, as well as the channel walls. This pattern persists
at 60 and 120 minutes of perfusion. C. The effect of PDMS absorption on BODIPY
glyburide transport in the placenta-on-a-chip model was also analyzed in acellular
devices. In this study, 1 μM BODIPY glyburide was perfused in the upper
microchannel, and fluorescence levels of the outflow from both microchannels were
quantified using a microplate reader. The maternal concentration of BODIPY
glyburide decreases slightly over the 150-minute perfusion. However, both the
maternal and fetal concentrations remain predominantly constant, suggesting that
PDMS uptake of drug does not increase significantly or exert a major effect on
measured levels over the course of our 3-hour transport studies.
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4.5B). The level of glyburide in the maternal compartment was maintained low without
significant changes over the entire duration of drug perfusion. Considering that BCRP is
absent in the endothelial cell population128, this observation indicates that the transportermediated efflux of maternally administered glyburide is governed predominantly by BeWo
cells in the microengineered placental barrier. Taken together, our results clearly illustrate
the insignificant transfer of glyburide across the microengineered placental barrier.

4.3.5. Biochemical inhibition of glyburide transport
To validate the active transport function of BCRP in our glyburide transport model, we next
measured the maternal concentration of BODIPY glyburide in the presence of Ko143,
which is a specific inhibitor of BCRP146,147. In these experiments, addition of 150 nM Ko143
to the glyburide-containing medium resulted in the reduction of fluorescence detected in
the maternal perfusate, as compared to the inhibitor-free condition (Figure 4.7A). This
change was statistically significant from 90 to 150 minutes of perfusion. Considering that
no structural changes of the placental barrier were observed during this period and
identical hydrodynamic conditions were maintained across all experiments, these data
suggest that Ko143 effectively reduced the transport function of BCRP and decreased the
amount of glyburide shuttled back into the maternal compartment from the BeWo cells.
This observation was further supported by increased intracellular green fluorescence in
the BeWo cells treated with Ko143 (Figure 4.7B). Despite this significant effect of a BCRP
inhibitor, however, no visible fluorescence was detected in the HPVEC population cultured
on the other side of the membrane, nor did the fetal concentration of glyburide significantly
increase over time (Figure 4.7C). This result implies that the reduced activity of BCRP
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during Ko143 treatment was still sufficient to limit the transfer of glyburide from the
maternal to the fetal compartments.

Figure 4.7. Inhibition of BCRP. A. Addition of Ko143, a BCRP inhibitor, results in
decreased maternal glyburide levels as compared to the control perfusion. This is
attributable to inhibition of efflux function of BCRP. B. The levels of fetal glyburide in the
inhibitor condition are not significantly different from those in the control group without the
inhibitor. Passage of glyburide to the fetal compartment remains very low over the course
of drug perfusion in both groups. C. Increased drug accumulation in BeWo cells due to
reduced activity of BCRP is evident from fluorescence imaging of the cells. D. In the
presence of the inhibitor, the cells show significantly higher levels of fluorescence,
suggesting increased intracellular drug retention. **** indicates p < 0.0001.

4.4. Conclusion
In this chapter, we have demonstrated the feasibility of utilizing the placenta-on-a-chip
platform for analysis of drug transport across the human placental barrier. Using glyburide
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as a representative medication, our data show the capability of the placenta-on-a-chip to
recapitulate the native function of efflux transporters and to mimic the limited placental
transfer of a maternally administered drug. While the physiological relevance of this model
has yet to be validated in a more systematic and rigorous manner, our findings are
consistent with previous reports of glyburide transport in the human placenta. For
example, the first randomized human trial to compare glyburide and insulin in women with
gestational diabetes showed that glyburide levels were undetectable in the cord serum of
any infant[30]. Similarly, studies using the gold standard ex vivo perfusion of the human
placenta reported uniformly low glyburide transport rates ranging from 0.62% to 3.9%,
which approximates those estimated in our model (5.6%)139,140.

Despite the demonstrated capabilities of our model, further studies are needed to
maximize its potential for the study of placental drug transport. Of particular importance is
that our system has been designed to mimic the placental barrier late in pregnancy, when
there is minimal distance between syncytiotrophoblasts and fetal capillaries. Thus, this
model is not appropriate for modeling drug transport in earlier stages of gestation. Given
the plasticity of placental structure, new engineering strategies need to be developed to
reconstitute the significant changes that occur in the microarchitecture of the human
placental barrier throughout pregnancy. For example, it may be possible to create a model
that incorporates cytotrophoblasts and interstitial stromal tissue to study the little known
process of transplacental drug transfer in the first trimester. Another important goal for
future investigation is to extend our analysis to other key transporters reported in the
human placenta and to evaluate the transfer of their substrate drugs in our model. These
types of studies may be limited by the transformed cells (BeWo) used in our current system
that fail to fully recapitulate the expression profiles of native transporters. To address this
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problem, work is required to incorporate stable culture of primary human villous
trophoblast cells into our system. Primary villous trophoblasts can be isolated from term
placentas using protocols similar to those developed for isolation of HPVECs. Since these
cells are post-mitotic and cannot be externally stimulated to proliferate, however, it is
challenging to establish and maintain confluent trophoblast monolayers. Furthermore, the
behavior of primary trophoblast cells under perfusion culture conditions has not been
investigated previously. Future studies are needed to address these potentially significant
challenges and to develop new strategies for generation and long-term maintenance of
structurally stable primary trophoblast barrier in microfluidic cell culture devices. Finally,
special attention needs to be paid to the absorption of drug compounds into PDMS. This
undesirable property is a particularly critical issue for drug screening that can significantly
alter the pharmacokinetics of small molecule therapeutics. Studies are necessary to
explore alternative materials or develop new strategies (e.g., engineering of PDMS
surface chemistry) to render cell culture chambers resistant to drug absorption.

In conclusion, our work represents a significant advance that may provide the impetus to
improve and innovate traditional models in reproductive toxicology. With increasing use of
medications during pregnancy, the paucity of preclinical models for predicting drug
transfer in the human placenta is emerging as a critical research challenge that also raises
serious public health concerns. The proof-of-principle demonstrated here may hold great
potential as a technical basis for developing new drug screening technologies to address
this important problem. Specifically, our model, with its current capabilities, may find
obvious and immediate applications in screening the likelihood of fetal exposure to a wide
variety of drug compounds currently in use or under development for use in pregnancy.
Beyond studies of placental drug transport, this platform also provides a robust means to
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systematically investigate how the structure and function of the placental barrier itself can
be altered in response to perturbations in the local environment due to various factors
including drugs, xenobiotics, pathogens, abnormal hemodynamics, disease-derived
biomolecules, and environmental toxicants. Another possibility to explore building upon
recent progress in the development of multi-organ microphysiological models is to link the
placenta-on-a-chip with other microfluidic devices containing different types of fetal cells
for analysis of not only placental transfer of drug compounds but also their beneficial or
adverse health effects on the developing fetus. We believe that the versatility of our
placenta-on-a-chip technology offers great promise for enabling significant progress in
various aspects of placental physiology and reproductive medicine.
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CHAPTER 5. Development an implantation-on-a-chip system

5.1 Introduction
Successful placentation is critical for progression of a healthy pregnancy. In our final aim,
we propose the development of a platform to study early placentation. At the onset of
pregnancy, the blastocyst adheres to the uterine wall and the process of implantation
begins. A population of cytotrophoblasts migrate from the blastocyst into the uterine wall
and differentiate into extravillous trophoblasts (EVTs), acquiring an invasive phenotype.
These EVTs then invade through maternal uterine stroma and mediate spiral artery
remodeling. This remodeling alters the uterine spiral arteries from low flow, high resistance
vessels to low resistance conduits capable of high rates of blood flow. The proper
coordination of these steps of implantation and spiral artery remodeling are essential for
establishment and maintenance of a successful pregnancy. Despite the importance of this
process, the fundamental mechanisms that govern trophoblast invasion are largely
unknown. Dysregulated trophoblast invasion can result in pregnancy disorders that put
both the mother and baby at risk. Conversely, excessive EVT invasion can result in
development of placenta accreta, a condition where the placenta anchors too deeply into
the uterine wall and causes maternal hemorrhage at the time of delivery. A mechanistic
understanding of how trophoblast invasion is regulated will enable researchers to
determine interventions and possibly develop novel therapeutics to treat these disorders
of pregnancy. Paracrine factors secreted by the cells of the maternal decidua and
autocrine factors secreted by EVTs are known to impact EVT differentiation and invasive
behavior148. The spatiotemporal changes in concentrations of these soluble factors in the
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uterine environment determines the extent of trophoblast migration and invasion. Various
growth factors, prostaglandins, cytokines, interleukins, and chemokines contribute by
either promoting or inhibiting EVT invasion. However, it has been difficult to study this
complex biochemical milieu in existing in vitro systems.

Figure 5.1. Soluble factors impacting extravillous trophoblast invasion.
Decidual cells secrete soluble factors that regulate EVT invasion by promoting or
inhibiting migratory function. Adapted from Knofler et al. 2012.

The current models used for investigating trophoblast migration are unable to replicate the
structural and multicellular complexity of the uterine environment. The dynamics of
trophoblast invasion seen in humans is not matched in other species, thus animal models
cannot be accurately applied to this area of placental physiology16. A great deal of
progress has been made using standard in vitro approaches, however they too fail to
address many aspects of the processes of EVT invasion and artery remodeling. For
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example, one commonly employed method for studying EVT migration is the Matrigel
invasion assay. In such studies, a porous transwell insert is coated with a very thin layer
of Matrigel. EVTs are then introduced into the apical compartment of the insert and
incubated for 24-72 hours149. The extent of invasion requires extensive processing using
methods such as hematoxylin and eosin (H&E) staining or scanning electron
microscopy150. While useful in elucidating the impact of soluble factors on rates of EVT
migration, the thin acellular layer of Matrigel does not recapitulate the complex
microenvironment of the decidual stroma.

We have endeavored to develop a microengineered model of the maternal decidua, or
implantation-on-a-chip that will enable co-culture of EVTs and the decidual cells that
influence EVT function. This model enables precise control of the relative spatial
distribution and composition of cells and therefore mimics 3D microarchitecture of the
maternal-fetal

interface

during

implantation.

This

is

made

possible

by

the

compartmentalized design of the microdevice and a microengineering approach to form
an ECM hydrogel that can encapsulate relevant cell types. Moreover, the design of our
system makes it possible to independently and specifically control and manipulate fluids
and extracellular matrices. This allows us to systematically vary microenvironmental cues
in order to delineate their effects on the EVT behavior. Finally, the IOC offers advanced
imaging and analysis capabilities. Since our microdevices are fabricated using optically
transparent PDMS, it is possible to directly observe, image, and quantitatively analyze
various biochemical and biomechanical responses relevant to the specific topics of our
investigation. For instance, the invasion of EVTs into the 3D decidual compartment can
be monitored using light and video microscopy to measure key biophysical parameters
such migration speed, residence time, and directionality. Combined with the ability to
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precisely control cells and their microenvironment, the imaging and analytical capabilities
of our model will greatly facilitate the mechanistic studies proposed in this application and
make major contributions to improving our fundamental understanding of EVT invasion
during placentation.

5.2. Materials and Methods
5.2.1. Cell Culture
Primary extravillous trophoblasts were isolated from primary tissue following a previously
published protocol151 and maintained in RPMI-1640 medium (Invitrogen) containing 20%
FBS and 1% penicillin/streptomycin (Gibco). Primary human endometrial microvascular
endothelial cells (HEMECs) were purchased from ScienCell and maintained in EGM-2MV
medium containing 5% FBS (Lonza). The HTR8/SVneo cell line (ATCC) was cultured in
RPMI-1640 medium (Invitrogen) containing 5% FBS and 1% penicillin/streptomycin
(Gibco).

5.2.2. Microdevice Fabrication
The microdevice was fabricated following a standard soft lithography protocol. PDMS was
mixed at a 10:1 ratio of base to curing agent, degassed, cast upon a silicon master, and
cured at 65°C. The upper slab contained a microchannel containing three microchannels
and a phase guide feature (50 µm W x 100 µm H). This slab was bonded to a thin PDMS
layer using the technique of PDMS stamping. Briefly, a thin PDMS mortar layer was
generated by spin coating PDMS (10:3 base to curing agent) on a Petri dish at 2500 rpm
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for 5 minutes. The upper PDMS slab containing microchannel features was placed on the
spin-coated dish to transfer the PDMS layer onto the microdevice surface. This upper slab
was then placed on an uncoated thin cured PDMS slab (approximately 2-5 mm thick).
Devices were cured at room temperature overnight for complete bonding.

5.2.3. Microfluidic Cell Culture
Following fabrication, the microdevice was sterilized with a 20 minute UV irradiation. Next,
a polydopamine (PDA) solution was prepared (2 mg/mL in Tris-HCl buffer) and injected
into the central microchannel (500 µm W). The PDA solution was incubated for 2 hours at
room temperature in the dark then rinsed twice with sterile distilled water. This coating
serves to anchor the ECM gel to the PDMS surface. To create the stromal tissue in the
central microchannel, growth factor reduced Matrigel (Corning) was mixed with an equal
volume of 8 mg/mL collagen I (Corning) to create a 50:50 Matrigel collagen gel mixture.
This solution was injected into the microdevice and then incubated for at least 30 minutes
at 37°C for gelation.

Following gelation, EVTs were subcultured, resuspended at a concentration of 3 x 106
cells/mL, and injected into the upper microchannel. Human fibronectin solution (0.10
mg/mL in PBS) was injected into the lower microchannel. The device was tilted at a 90
degree angle and incubated at 37°C for 1 hour to enable EVT attachment to the gel
surface. After EVT adhesion was confirmed, HEMECs were injected into the lower
microchannel at a concentration of 6 x 106 cells/mL. Following a 1 hour incubation for
HEMEC attachment, a reservoir slab was conformally bonded to the microdevice surface
and filled with media for cell feeding. Media was changed every 24 hours.
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5.2.4. Exposure to TGF-beta
In order to test the effects of TGF-beta on EVT migration, both trophoblast and endothelial
cell media were supplemented with recombinant TGF-beta 1 (10 ng/mL; R&D Systems).
Media in each microchannel reservoir was changed every 24 hours.

5.2.5. Immunofluorescence Analysis
For each step in the immunofluorescence staining process, devices were placed on a
rocker to maximize penetration of solutions into the Matrigel/collagen I gel layer. First, the
microdevice was fixed with 4% paraformaldehyde for 15 minutes at room temperature
followed by permeabilization with 0.25% Triton X-100 for 10 minutes at room temperature.
The device was thoroughly washed with PBS after each incubation step. Next, the
microchannels were filled with 2% bovine serum albumin (BSA) and incubated for 1 hour
at room temperature. Primary antibody diluted in 2% BSA was then injected into the
microchannels and incubated overnight at 4°C. Next, the device was thoroughly washed
with PBS. Secondary antibody was diluted in 2% BSA, introduced into the microdevice,
and incubated overnight at 4°C. Nuclei were labeled with DAPI. Images were acquired
using a confocal laser-scanning microscope (Leica TCS SP8). Image processing and
generation of three-dimensional renderings were carried out using Volocity (PerkinElmer).
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5.2.6. Analysis of Invasion Area
Images were acquired daily during microfluidic cell culture using an epifluorescence
microscope (Zeiss Axio Observer). FIJI was utilized to quantify the area of EVT invasion
(Figure 5.2). First, the time course images were cropped to a field of view that only
included the gel channel. Next, the CellTracker channel was thresholded to segment the
invading EVTs. A binary image was generated based on this thresholding and a count of
white and black pixels was performed. Percent invasion area is reported as the number
of white pixels compared to total pixel area.

Figure 5.2. Image Analysis of Invasion Area. A. A 5X tile scan image is acquire
every 24 hours during the experimental culture period. During analysis, the area of
the gel that intervenes between the EVT and EC channels is selected and cropped.
B. The CellTracker channel is converted to grayscale and thresholded to segment
for EVTs. C. A binary image is generated and a pixel count enables quantification of
percent area of invasion.
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5.2.7. Statistical Analysis
Results are reported as mean ± S.E.M. Statistical significance was assessed using a twotailed Student’s t-test or analysis of variance (ANOVA). Each experiment was repeated
at least three times.

5.3. Preliminary Results and Discussion
5.3.1. Recapitulating EVT decidual invasion
The three-dimensional microenvironment of the uterine decidua and its resident cell types
are critical to the process of EVT migration and subsequent spiral artery remodeling that
occur in human pregnancy. Previous work to study human implantation in two-dimensional
in vitro platforms like Transwell inserts have not been able to accurately model this
complex microarchitecture. In the implantation-on-a-chip system, we have developed a
platform that reconstitutes key aspects of this decidual milieu (Figure 5.3A). The central
channel of the microdevice contains an ECM gel that serves to recapitulate the stromal
decidua. It is flanked on either side by two additional microchannels. One microchannel is
lined with ECs and thus models a uterine spiral artery. Invading EVTs are cultured in the
opposite microchannel (Figure 5.3C).

Initial proof-of-concept work for the implantation-on-a-chip was carried out using the
HTR8/SVneo cell line as to model human EVTs and growth factor reduced Matrigel as the
ECM substrate in the central gel microchannel. As illustrated in Figure 5.3D, HTR8 cells
began invading within 24 hours of culture. These cells progressively migrated through the
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ECM stroma and reached the endothelial cell channel within 96 hours of microfluidic
culture. The use of a polydopamine pre-treatment in the central microchannel during
microdevice fabrication ensures sustained anchorage of the ECM hydrogel to the PDMS
surface. Therefore, as EVTs migrate and remodel the ECM of the stromal compartment,
the hydrogel remains firmly adhered to the microchannel surface and does not detach due
to cellular contractile forces.

Figure 5.3. Implantation-on-a-chip system. A. Schematic of in vivo EVT migration
in the maternal decidua. First, cytrophoblasts (CTBs) differentiation into an
extravillous phenotype. These EVTs then migrate through the uterine stroma
towards the maternal spiral arteries. This process is influenced in part by paracrine
factors secreted by stromal cells (SCs) and endothelial cells (ECs) in the uterine
microenvironment. B. Photograph of the IOC microdevice. The three compartment
system allows for reconstitution of the uterine stroma on-chip. C. The IOC
microsystem consists of three main compartments: an EVT channel, ECM hydrogel
compartment, and EC channel. This platform enables co-culture of three cell types
critical to implantation: EVTs, decidual stromal cells, and ECs. D. EVTs cultured in
the side channel invade into the central ECM gel and migrate towards the EC
compartment.
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In order to improve the physiological relevance of the implantation-on-a-chip system, two
important changes were made following our initial proof-of-principle studies. We replaced
the use of the HTR8/SVneo cell line with primary extravillous trophoblasts freshly isolated
from first trimester placental tissue using a previously published protocol. These cells can
be maintained in in vitro culture for several passages following isolation. This is an
important advance, as a great deal of questions exist regarding the similarity of the
HTR8/SVneo cell line to primary EVTs and purity within the cell line. A recent study
showed that the cell line contains a mixed population of cells, with a combination of
cytokeratin 7-positive trophoblast cells and vimentin-positive stromal cells152. This
heterogeneity reduces the physiological accuracy of the implantation-on-a-chip model.

Figure 5.4. Primary EVT invasion is enhanced by the presence of HEMECs.
EVTs invade from the upper microchannel through the ECM gel in monoculture (top
row) and co-culture (bottom row) conditions. Migration of EVTs occurs in both
conditions, highlighting the inherent invasiveness of the cells. The degree of invasion
is increased in co-culture with HEMECs as compared to EVT monoculture. This
highlights the role of endothelial cells in regulating EVT invasion.
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Thus, primary cells are a better alternative for studies of EVT invasion. Additionally, we
tested various ECM hydrogels to optimize the composition of the on-chip microengineered
uterine stroma. This optimization work concluded with the use of a 50:50 combination of
growth factor reduced Matrigel and collagen I. This ECM mixture is a more accurate model
for the uterine stroma than Matrigel alone because the tissue in vivo is rich in both
collagens and laminin. With this change, we observed an increase in 3D EVT invasion as
opposed to 2D migration in the case of Matrigel alone.

Work in the updated experimental setup utilizing primary EVTs and growth factor reduced
Matrigel/collagen I ECM tissue is illustrated in Figure 5.4. Here, the primary EVTs migrate
through the ECM channel more quickly than HTR8 cells, reaching the endothelial cell

Figure 5.5. A. Top-down view of the implantation-on-a-chip at 72 hours of culture.
EVTs have reached the endothelial cell compartment. Cells are stained for F-actin
(green) and nuclei (blue; DAPI). Laminin present in the ECM is stained red. B. An
isometric view of the microdevice illustrates the 3D invasion of EVTs and endothelial
tube in the EC channel. C. A zoomed view of the hydrogel-EC interface depicts the
areas at which EVTs come into direct contact with HEMECs.
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compartment by 48 hours of culture. In order to better understand the contribution of
human endometrial microvascular endothelial cells (HEMECs) to EVT migratory behavior,
we compared EVT monoculture to EVT/HEMEC co-culture (Figure 5.4). Over three days
of microfluidic culture, primary EVTs in both conditions migrate through the engineered
stromal compartment and reach the opposite microchannel. The rate of migration is
increased in the co-culture group, suggesting that HEMECs secrete factors that enhance
EVT invasiveness. However, EVTs do reach the opposite microchannel within 72 hours in
monoculture conditions. Thus, autocrine factors produced by EVTs and signals from the
Matrigel/collagen I matrix may also impact EVT behavior in the absence of ECs.

Confocal imaging of immunofluorescence staining illustrates 3D EVT invasion through the
Matrigel/collagen I matrix (Figure 5.5A-B). EVTs have reached the EC compartment and
begun to integrate into the endothelial cell monolayer, as illustrated by the high
magnification view in Figure 5.5C.

5.3.2. Exposure to TGF-beta reduces EVT invasion
One of the main goals in the development of the implantation-on-a-chip system is to utilize
it to discover novel regulators of EVT invasion and to better understand the contributions
of the various cell types of the decidua on regulating EVT migration. Research from the
past several decades has generated a list of soluble factors, such as cytokines and
hormones, that act to either promote or inhibit EVT invasion during implantation148. One
factor that has been shown in many studies to reduce EVT migration is transforming
growth factor beta (TGF-b). It is produced by several cell types present in the decidua,
including stromal and immune cells. Clinically, elevated levels of TGF-b early in pregnancy
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have been associated with preeclampsia, suggesting it may play a role in inhibiting EVT
invasion during implantation153,154. Given the body of knowledge surrounding TGF-b, we

Figure 5.6. Effects of TGF-b treatment. A. TGF-b reduces EVT migration compared
to untreated devices in both monoculture and co-culture groups. Microdevices were
imaged at 72 hours of culture. EVTs are stained with CellTracker Green and nuclei are
labeled in blue with DAPI. B. The percent area of invasion over time in the gel lane
was quantified using FIJI image analysis. Treatment with TGF-b reduced the degree
of EVT invasion compared to untreated control. Light purple = 24h, blue = 48h, dark
purple = 72h.
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chose to perform proof-of-concept experiments with it to validate that the implantation-ona-chip is capable of recapitulating the physiological response to the cytokine.

In our TGF-b studies, cells cultured in the implantation-on-a-chip device were treated with
the cytokine for the duration for culture through supplementation to both the EVT and EC
media. Both EVT monoculture and EVT/EC co-culture conditions were tested and these
devices were compared to untreated control monoculture and co-culture groups. Overall,
treatment with TGF-b reduced EVT invasion in both monoculture and co-culture
conditions. At 72 hours of culture, fewer EVTs had reached the EC channel and integrated
into the endothelial monolayer, as illustrated in Figure 5.6A. In EVT/EC co-culture, TGF-b
treatment resulted in a 33% reduction in percent area invaded compared to an untreated
control (Figure 5.6B).

5.3.3. Incorporation of stromal cell culture
Decidual cells located in the uterine stroma play an active regulatory role in influencing
EVT migration during implantation148. These cells are hypothesized to be gatekeepers in
the process of implantation that limit EVT invasion through production of factors like tissue
inhibitors of metalloproteinases (TIMPs)
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. Despite the importance of these cells in

regulating EVT invasion, very few in vitro systems utilized in studying implantation
incorporate stromal cell culture. In part, this is due to limitations of the platforms used. For
example, it is difficult to add 3D culture of fibroblasts in a Transwell insert. The design of
the implantation-on-a-chip system, however, is well-suited to integration of culture of
human uterine fibroblasts (HUFs) in the ECM microchannel. The organ-on-a-chip design
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enables tunable control over the make-up of the microengineered stromal tissue.
Moreover, the addition of these cells to the stromal compartment further improves the
physiological relevance of our microengineered model.

For fibroblast culture on-chip, HUFs are introduced into the gel precursor solution and thus
embedded in the Matrigel/collagen matrix in the central microchannel after gelation. HUFs
attach to the matrix, spread, and proliferate over the course of microfluidic culture, as
illustrated with CellTracker Red-stained cells in Figure 5.7. This 3D culture mimics the
microarchitecture of uterine stroma where fibroblasts reside in vivo and the three-cell co-

Figure 5.7. Human uterine fibroblast culture on-chip. At left, a phase microscopy
image depicts the co-culture of EVTs, HUFs, and ECs. The upper right image shows
CellTracker Green-stained EVTs and the lower right shows CellTracker Red-stains
HUFs from the zoomed field of view outlined in red.
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culture design more closely reconstitutes the multicellular makeup of this tissue. The
incorporation of stromal cells will allow mechanistic analysis of the contribution of HUFs
to EVT migration.

5.4. Conclusion and Future Directions
We have demonstrated the preliminary steps towards a microphysiological model
of human implantation in this chapter. This is the first platform to use
microengineering techniques to study the interactions between EVTs, the uterine
stroma, and endometrial endothelium. Another group has employed a microfluidic
system to probe EVT migration, however this platform involves trophoblast
monoculture and lacks the physiological relevancy of our implantation model156.

Moving forward with these studies, it will be important to decidualize the uterine
fibroblasts cultured on-chip. Decidualization occurs after in the endometrium after
ovulation in the menstrual cycle and makes the tissue amenable to supporting
pregnancy. A variety of hormones, especially progesterone, dictate this process
and uterine fibroblasts are transformed into epithelioid, secretory decidual stromal
cells (DSCs). This process is necessary for implantation to take place and the
decidualized lining is shed if pregnancy does not occur. The standard in vitro
protocol to decidualize endometrial stromal cells requires treatment with a cocktail
of hormones and cyclic AMP157. However, a recent study by Menkhorst et al. found
that EVTs produce factors that that enhance decidualization in the uterine
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stroma158. Thus, it is of interest to study this in our system and probe whether the
presence of invading EVTs serves to decidualize HUFs on-chip. If these effects
are not observed in the microengineered implantation model, we can utilize the
standard decidualization protocol of hormone treatment.

We will also examine integrin switching in the implantation-on-a-chip system.
During EVT invasion, there are coordinated changes in integrin expression that
regulates normal migratory behavior. Cytotrophoblasts exhibit high levels of a6
expression, whereas EVTs that have begun to invade show upregulation of a5b1
and a1b1. Inhibition of integrin switching or integrin-ECM interactions results in
decreased EVT migration159. We will take advantage of the ability to visualize cells
in the ECM environment at high magnification and resolution and characterize
integrin expression on-chip using immunofluorescence analysis. Furthermore, we
will quantify changes in gene expression using qPCR.

We

are

also

interested

in

leveraging

microengineering

techniques

of

vasculogenesis in this implantation model. Researchers in the field of organ-on-achip technology have demonstrated the ability to generate self-organizing vessel
networks within a hydrogel matrix in microengineered tissue models through
culture of endothelial cells and supporting stromal cells160,161. Remarkably, through
specialized protocols of microfluidic cell culture, these vessels become perfusable
after forming162. In the implantation-on-a-chip, we plan to investigate vessel
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network formation using endometrial endothelial cells and uterine fibroblasts in the
gel microchannel. Following on-chip vasculogenesis, EVTs will be introduced into
the side channel and their migratory behavior would be tracked. With this design,
we have the potential to study EVT-mediated remodeling, as the vessels are
completely free-standing and surrounded by ECM. Furthermore, with perfusable
vasculature, we can quantify changes in flow and resistance patterns. Since
changes in vascular resistance are one of the most important outcomes of EVT
remodeling in vivo, an in vitro platform capable of recapitulating this process would
be valuable in placental biology research.

Ultimately, the implantation-on-a-chip system represents an opportunity to improve
our understanding of the myriad of factors that influence EVT invasion and spiral
artery remodeling in human pregnancy. Our multicellular system enables
examination of the role of various uterine cell types on these physiological
processes. Furthermore, this technology allows for the use of patient-specific
samples. There is the potential to culture EVTs from women affected by disorders
like preeclampsia or placenta accreta in order to uncover the mechanistic bases
of these complications of pregnancy.
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CHAPTER 6. Conclusion and Future Directions

6.1. Overview of microengineered placental models
The work presented in this thesis has focused on the development, characterization, and
validation of the placenta-on-a-chip, a microphysiological in vitro model of the human
placental barrier. In Chapter 2, the design and characterization of the placenta-on-a-chip
system was discussed115. Generation of a trophoblast-endothelial cell bilayer tissue was
evaluated and subsequently the microengineered platform was used to study maternalfetal transport of glucose, a nutrient that is essential for fetal growth and development. The
platform was validated by comparing on-chip glucose transport results to existing data
sets from ex vivo placental perfusion and in vivo clinical studies. This work was expanded
upon in Chapter 3, where the placenta-on-a-chip was leveraged to investigate the impact
of fluid shear stress on trophoblast function and differentiation. Finally, in chapter 4, the
system was utilized to study placental drug transport in order to address the need for
methodologies to screen for drug safety in pregnancy117. The transfer of fluorescently
conjugated heparin and glyburide was analyzed to demonstrate proof of concept of the
utility of the placenta-on-a-chip platform in this field.

We have presented the development and preliminary characterization of the implantationon-a-chip in Chapter 5. This microphysiological system reconstitutes the multicellular
milieu of the uterine decidua with an endometrial endothelial cell channel, fibroblast-laden
stromal tissue, and invading extravillous trophoblasts. In the work outlined in chapter 5,
we have optimized the parameters of this model like cell sourcing and ECM optimization.
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We have also begun the process of validating this model through examination of the
effects of TGF-b treatment and its inhibitory effects on EVT migration. However, further
validation is necessary with additional pro- and anti-migratory factors to validate the
physiological relevancy of the platform. There a variety of additional outcomes that will be
tested in the implantation-on-a-chip, including progression of integrin switching during EVT
migration and discovery-based analysis of factors secreted by cells on-chip. The goal is
to move from validation of the platform using factors established to influence implantation
to discovery of novel regulators of this process.

6.2. Limitations and Future Directions
6.2.1. Cell Sourcing
The choice of what cell type to utilize in in vitro research remains a fundamental question
for all biomedical researchers. In our work on the placenta-on-a-chip system, we have
used the BeWo cell line. While this cell type, and in particular the b30 subclone, is widely
employed as a model for villous trophoblasts, the use of cell lines in research is associated
with a variety of limitations as discussed in chapter 1. Primary cells that have been
recently isolated from their native in vivo environment are regarded as more biologically
relevant than cell lines and thus preferable for use in in vitro research. We have tested the
use of primary human villous trophoblasts (HVTs) isolated from placentas following term
delivery in the placenta-on-a-chip. Since HVTs are post-mitotic and do not proliferate in in
vitro culture, it is challenging to generate a fully confluent monolayer in Transwell or
microfluidic cell culture164. To address this obstacle, we amended the device setup
protocol to include a second round of seeding of a high density cell suspension in order to
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maximize attachment on the ECM-coated membrane. This led to establishment of a nearly
confluent monolayer, as shown in Figure 6.1A. The HVTs cultured on-chip demonstrated
signs of syncytialization, with areas of nuclear aggregation, as well as microvilli formation
on the cell surface (Figure 6.1B-C). Interestingly, syncytialization occurs spontaneously at
21% oxygen in primary villous trophoblasts and does not require the use of exogeneous
chemical mediators like in BeWo b30 cells. Future studies should focus on the effects of

Figure 6.1. On-chip primary villous trophoblast culture. A. Primary human villous
trophoblasts (HVTs) stained with Cell Tracker Green cultured in the placenta-on-achip form a nearly confluent monolayer. Scale bar = 250 µm. B. HVTs exhibit areas
of nuclear aggregation. Nuclei stained with DAPI in blue. Scale bar = 50 µm. C.
Microvilli formation has occurred on the apical surface of HVTs, as shown with Factin in green. Scale bar = 20 µm.
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mechanical forces on primary villous trophoblast phenotype and function in the placentaon-a-chip system to build upon the work outlined in Chapter 3 of this dissertation.

Figure 6.2. Stem cell-derived trophoblasts. A. H9 embryonic stem cells treated
with BMP4 (100 ng/mL) exhibit morphological changes during differentiation
compared to an FGF2 (4 ng/mL) control. In the BMP4-treated cells at top, cells begin
to look epithelial-like by day 4 of culture, indicating the start of differentiation of
trophoblast cells. This change is not observed in the FGF2-treated control. B.
Syncytialization is present in a population of iPSC derived trophoblasts at day 7. The
black boxes delineate multinucleated syncytiotrophoblast cells. A single cell in the
lower right panel contains 7 nuclei.

Stem cell-derived trophoblasts represent another option for a creating a physiologically
relevant placental barrier model. We have worked with the University of Pennsylvania
Stem Cell Core to generate trophoblasts derived from both embryonic stem cells (H9 line)
and induced pluripotent stem cells (iPSCs) following the protocol published by Xu et al60.
Each stem cell type was treated with bone morphogenetic protein-4 (BMP-4) over the
course of 7 days. As illustrated in Figure 6.2A, morphological changes were apparent in
the BMP4-treated cells by day 4 of culture as they became more epithelial-like in
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appearance.

At

day

7,

phase

contrast

imaging

showed

the

presence

of

syncytiotrophoblast cells, where there was evidence of nuclear aggregation within a single
cell (Figure 6.2B). Gene expression analysis demonstrated a decrease in mesoderm and
pluripotency markers with a concomitant increase in trophoblast cell markers, such as
cytokeratin 7, HLA-G, and human chorionic gonadotrophin alpha and beta, indicating
successful differentiation to a trophoblast-like cell type. Finally, quantification of hCG-b
indicated that trophoblasts derived from both embryonic stem cells and iPSCs began to
secrete the protein around day 6 of BMP4 treatment. Taken together, these data establish
the potential of generating stem cell-derived trophoblasts for use as an alternative to
primary trophoblast villous cells in the placenta-on-a-chip.

6.2.2. Immune considerations
The changes that occur in the maternal immune system during pregnancy are a
remarkable phenomenon that is unique in human biology. The fetus is a semi-allograft
that, in normal pregnancies, avoids immune system recognition and rejection.
Furthermore, the development of the placenta draws parallels to cancer and tumor
progression, yet complex immune coordination regulates placentation in a manner that
does not occur in cancer pathophysiology. The work presented in this dissertation on
creating microphysiological models of the human placenta has not yet incorporated
components of the maternal or fetal immune system. However, these are an important
consideration in designing future studies utilizing these microengineered platforms. In the
placenta-on-a-chip, there is the potential to investigate the immune function of the
maternal-fetal interface by introducing resident Hofbauer cells to the microengineered
placental barrier or studying trafficking of maternal immune cells to the placental barrier in
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the presence of infection165. This system could also be used to analyze maternal-fetal
transfer of immunoglobulin G (IgG), which occurs starting in the first trimester and
continues throughout pregnancy, and is essential to early development of immune
protection in the fetus166-168. The Fc neonatal receptor (FcRn) has been shown to mediate
IgG transfer, but recent work indicate there may be additional mechanisms that contribute
to this process169. Therefore, the placenta-on-a-chip could be applied to these questions.
There is even the potential to leverage this system to better understand the effects of
maternal vaccines at the placental barrier and thus inform decisions regarding the timing
and efficacy of maternal immunizations in pregnancy. For example, several
pharmaceutical companies are currently developing maternal vaccines to respiratory
syncytial virus (RSV). RSV is a public health threat as it can cause severe morbidity and
mortality in premature babies and infants. Maternal vaccination against RSV represents
an opportunity to protect these vulnerable population. The placenta-on-a-chip could be
employed to test antibody transfer following use of a maternal RSV vaccine.

There are a multitude of opportunities to incorporate immune components to the
microphysiological model of implantation. In implantation, EVTs invade and remodel the
uterine arteries by replacing the cells of the endothelium in the spiral arteries. In the
implantation-on-a-chip system, we have focused on the regulatory contributions of the
endothelial cells of the maternal vasculature as well as the neighboring stromal cells.
However, immune cells located in the decidua also have a significant role in normal
progression of implantation. Uterine natural killer cells (uNK), T cells, decidual
macrophages, and immature dendritic cells located in the uterine stroma all modulate EVT
function during spiral artery remodeling170. In early pregnancy, flow cytometry analysis has
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demonstrated that uNK cells are the most abundant immune cell type, making up
approximately 70% of the population of leukocytes in the decidua171. These uNK cells
secrete a variety of factors that influence implantation, including cytokines, MMPs, and
pro-angiogenic factors. Studies have established both uNK-mediated promotion and
inhibition of EVT invasion172. This suggests that uNK cells, along with other decidual
leukocytes, play an active role in determining the balance between under- and overinvasion of EVTs. There is also evidence of immune cell dysregulation in disorders of
pregnancy like preeclampsia. For example, a recent study demonstrated that NK cells
were activated in response to placental ischemia in a mouse model of preeclampsia,
indicating this immune cell type may play a role in the pathogenesis of disease. In turn,
this finding may represent an opportunity identify druggable targets in preeclampsia, which
currently lacks any effective treatments. In our microengineered implantation model,
immune cells can be introduced by embedding them directly in the ECM tissue or flowing
them through the endothelial cell channel. The precise spatiotemporal control over the onchip microenvironment that is possible in our platform can allow for mechanistic
examination of immune cell function and potentially even response of immune cells to
investigational drugs. This can provide important information regarding the regulatory role
of immune cells in EVT invasion and spiral artery remodeling.

6.2.3. Microdevice design optimization
Another important aspect of future work on these microphysiological models of the human
placenta relates to the optimization of microdevice design and culture protocols. The
widespread adoption of organ-on-a-chip technology is currently limited by the fact that it
requires an experienced technician to fabricate microdevices and run microfluidic cell
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culture experiments. Moreover, the throughput of organ-on-a-chip studies lags behind the
capabilities of standard in vitro approaches that can utilize 96- and 384-well plates to
achieve numerous experimental replicates in a given study173. Therefore, future work on
placenta-

and

implantation-on-a-chip

technologies

should

focus

on

technical

improvements to increase experimental efficiency. In particular, there is opportunity for
innovation in the experimental setup for perfusion microfluidic culture, which currently
requires a syringe reservoir and tubing connections to a large syringe pump. The footprint
of the syringe pump system is orders of magnitude larger than that of the microdevice and
thus limits the number of devices that can be run in a single cell culture incubator.

The syringe reservoir employed in the studies in this dissertation also increases the overall
footprint of the microdevice as well as necessitates time-intensive experimental setup. An
improved media reservoir design that streamlines experimental setup as well as
parallelization of replicate microdevices will vastly improve throughput of organ-on-a-chip
experiments. This capability would transform organ-on-a-chip technology and make it
amenable to the high throughput experiments used by large pharmaceutical companies.
Furthermore, the ability to integrate on-chip sensors would also revolutionize the field and
various groups are currently working in this area174. For example, real time on-chip sensing
of nutrient concentrations in the placenta-on-a-chip would permit an unprecedented look
at the temporal maternal-fetal nutrient transport profile and provide an opportunity to
investigate acute changes in transport in response to environmental perturbations. The
use of on-chip sensors would vastly improve the efficiency and ease of the glucose
transport studies conducted in Chapter 2 of this dissertation.
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Another limitation of current organ-on-a-chip systems is the use of PDMS as the material
for fabrication of microdevices. PDMS is one of the most widely used silicon polymers with
far-reaching applications ranging from microfluidic devices to cosmetics to food additives.
Surprisingly, the material used to fabricate the devices discussed in this dissertation can
be found in trace amounts in McDonald’s chicken nuggets. PDMS is easily prototyped,
transparent, and gas permeable, thus making it a suitable material for lab-on-a-chip and
organ-on-a-chip studies. However, a major limitation of PDMS relates to the fact that it
can absorb small molecules like drugs and hormones, which can potentially impact
microfluidic cell culture experiments175. This is especially relevant to our work in using our
microengineered model of the human placental barrier to study maternal-fetal drug
transport. Outcomes may be affected by sequestration of drug in the bulk PDMS and this
rate of absorption will vary depending on characteristics of an individual drug. Similarly,
small hormones like estrogen have been shown to be taken up by bulk PDMS and thus
could also affect studies of placental cell function. Some groups working in the organ-ona-chip field have begun to test use of other materials, such as poly(methyl methacrylate)
(PMMA), that do not have this problem. Therefore, in addition to devising high throughput
approaches to organ-on-a-chip models, attention in future work should be paid to
identifying alternative materials for constructing the placenta-on-a-chip and implantationon-a-chip microdevices. These will be important steps in maximizing the impact of
microphysiological models on progress in the field of placental biology.

In our work on the placenta-on-a-chip system, we have utilized a semipermeable
polycarbonate membrane as a culture scaffold to mimic the basement membrane
structure of the human placental barrier. This porous polymeric substrate enables
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compartmentalization of the maternal and fetal microchannels on-chip and is coated with
human fibronectin to support cell adhesion and culture. It is structurally and functional
similar to porous membranes of Transwell inserts that are widely used in conventional in
vitro cell culture protocols. However, the synthetic polymers used in these membranes are
considerably different than the native ECM of the in vivo basement membrane. Polymeric
membranes do not recapitulate the cell-ECM interactions that are critical to cell attachment
nor the material properties and porosity of the native basement membrane. The porosity
of these polymeric membranes is also different than that of the native basement
membrane. Motivated by this problem, our lab has developed a method to generate
decellularized ECM-derived (dECM) membranes for organ-on-a-chip applications and we
seek to apply this technique to the placenta-on-a-chip system. Briefly, the multi-step
membrane fabrication process involves decellularization of native tissue, generation of an

Figure 6.3. Techniques for fabrication of decellularized ECM membranes. A. A
side view highlights the thinness of a decellularized ECM membrane. Tweezers are
used to pull a dECM membrane off the surface of a slab of PDMS. B. Our lab’s
proprietary dECM membrane fabrication techniques enable generation of an
extremely transparent membrane, as highlighted here (membrane placed over the
word “decellularization” in the center of the image). This is an essential property for
cell culture applications, as membrane transparency enables visualization of cells
cultured on the dECM substrate using conventional epifluorescence and confocal
microscopy.
126

ECM hydrogel, vitrification to a thin film membrane, and integration into a microfluidic
device176. In the context of our microengineered placental barrier model, we can use the
approach developed by Mondrinos et al. to create membranes derived from placental
ECM material that is decellularized and processed following published protocols177. The
incorporation of a placental decellularized ECM (dECM) membrane would improve the
physiological relevance of the placenta-on-a-chip platform. Future work should endeavor
to fabricate and characterize such scaffolds in this microengineered system.

6.2.4. Emerging opportunities in placental biology research
The studies presented in this dissertation represent an important in advance in the fields
of placental biology and organ-on-a-chip technology. Our work on the placenta-on-a-chip
is the first example of microengineering approaches to be utilized to examine the human
placental barrier and has the potential to continue to impact placental research. There
remains an opportunity to expand upon the study of glucose transport presented in
Chapter 2 of this dissertation and continue testing placental nutrient metabolism and
transfer in the placenta-on-a-chip. Nutrient availability and transport is fundamental to fetal
growth and therefore to the process of fetal programming. Thus, an improved
understanding of placental nutrient transfer could influence the practice of clinical care
during pregnancy and impact the perinatal and lifelong health of a child. The placenta-ona-chip can be used to be study transport of amino acids, fatty acids, and more. There is
also the opportunity to leverage the placenta-on-a-chip to investigate fetal-to-maternal
transport of metabolic waste products. As discussed in Chapter 1, the placenta serves as
a conduit to remove fetal metabolic waste as the developing liver and kidneys are not
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functional in this capacity in utero. Little research has been conducted with regards to
placental waste transfer so there is potential to uncover the role it plays in fetal
development or possibly in adverse pregnancy outcomes. Furthermore, in the area of
maternal-fetal drug transport, we envision continued use of the placenta-on-a-chip in
screening additional medications. The proof-of-principle work in Chapter 4 in screening
heparin and glyburide is just a starting point for this important application of the placentaon-a-chip and we plan to continue to analyze maternal-fetal drug transfer as a tool to
predict drug safety in pregnancy. However, it will be critical moving forward to develop a
method to test the transfer of unconjugated drug on-chip, as the presence of a conjugated
fluorophore in our preliminary studies likely alters drug pharmacokinetics at the placental
barrier. This change in experimental setup as well as technical improvements in the
efficiency of device design (as discussed in Chapter 6.2.3) will allow the placenta-on-achip to be used in an area of research that is in dire need of effective and accurate
screening tools.

There is a great deal of interest in the organ-on-a-chip community in linking separate tissue
chip systems to create what is sometimes referred to a “body-on-a-chip” platform163. In
these setups, separate microengineered organ models are connected in order to emulate
and study inter-organ interactions and physiology. This is of particular interest in the field
of preclinical drug development, as drugs most often fail Phase I safety clinical trials when
adverse effects are reported. A multiorgan body-on-a-chip system could potentially enable
detection of these organ toxicities that are not found through animal testing. With regards
to the work presented in dissertation, linking the placenta-on-a-chip to microphysiological
models of maternal or fetal organs would enable entirely new studies of complex
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pregnancy physiology. In particular, in addition to investigating drug transport in the
placenta-on-a-chip, connection to fetal organ models would allow for examination of drug
safety in the developing fetus. Furthermore, linkage to maternal organ models could
uncover how maternal physiology affects placental function and development, which
would be of particular interest in modeling pathological conditions like IUGR to ascertain
how maternal disease in other organ systems impacts the placenta.

In addition to development of “body-on-a-chip” systems, organ-on-a-chip technology can
be employed to create microphysiological models of human disease. Future work on the
microengineered systems presented in this dissertation should focus on creation
pathophysiological models of pregnancy. For example, one could develop a placenta-ona-chip model that recapitulates gestational diabetes or an implantation-on-a-chip system
to mimic preeclampsia. These platforms could be used to better understand disease
pathophysiology as well as potentially uncover new therapeutic modalities for disorders of
pregnancy. There is also the opportunity to use patient-specific primary cells to create
platforms that allow for a more personalized medicine approach in placental biology
research. For instance, we can utilize primary EVTs, fibroblasts, and endothelial cells from
a patient with preeclampsia to evaluate the behavior and function of these cells on-chip.

Overall, the work presented in this dissertation outlines one of the first applications of novel
microengineering technologies to the field of placental biology. The placenta is a
remarkable organ and an improved understanding of how it functions will better the lifelong
health of mothers and babies alike. I believe the organ-on-a-chip systems we have
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developed here represent the first step towards advances in research that will enable
researchers and clinicians to develop treatments for adverse pregnancy outcomes and
improve maternal and fetal care. This is a field that truly affects every single individual
worldwide and it will continue to grow as awareness of its importance increases.
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